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 Introducing metals 
eyond myths and beliefs, metals have drawn noticeable 
attention throughout centuries because of (mostly supposed 
rather than actually proven) medicinal virtues. Copper, arsenic, 
mercury and the entire precious metals series have been deployed 
either for rational and for the most odd and awkward purposes, 
from water sanitisation, wound healing, not missing boosting 
fertility, dental care and almost every bizarre remedy one could 
possibly figure out. Yet, there has been an ounce of truth likewise 
each worthy tale. 
The exploiting modern medicine progressively led to prove many 
metal-based drugs to be highly effective against sundry disorders, 
diseases and syndromes. Since then, a sweeping set of metal 
complexes has been synthesized for pharmacological purposes in 
many fields. Anticancer is intelligibly the foremost nowadays, but 
endeavours have been spent also for sampling metallo-drugs as 
anti-inflammatory, antibacterial, anti-rheumatic, and antimalarial 
and more.1-4  
The distinctive electronic configuration is the very reason making 
transition metals such a unique item in the anti-cancer weaponry 
as it confers distinctive characteristics and offers great versatility, in 
terms of the ability to tune the properties of a given molecule. It 
translates in the chance to fine develop key pharmacological aspects 
such as selective drug activation and delivery. 
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 Platinum 
Metal-based drugs have come to the scene as effective anti-cancer 
drugs in the between of late 50s and late 60s thanks to Francis 
Dwyer, who first learned about the ruthenium polypyridyl 
anticancer qualities,5-7 and Barnet Rosenberg, who kick started the 
vigorous research towards anti-cancer active platinum-based 
compounds back in 1969, after his findings on the very first 
Pt-based anti-tumour medicine: the cisplatin, cis-di-ammino-di-
chlorido-platinum(II).8 Cisplatin has eventually become the very 
first FDA-approved metal-based anticancer drug back in 1979, yet 
used to the treatment of testicular, ovarian, bladder, lung, and 
head-neck cancers.9,10 
The cisplatin effectiveness, tough not yet wholly understood, 
ascribes to its ability to bind nuclear DNA.11 Anyhow, its cellular 
uptake is known to depend on the interaction with the CTR1 
copper-transport protein.12-14 Remarkably, it is nowadays clear 
DNA is not the exclusive target for most metallo-drugs: rather than 
simple sparring partners, proteins play as starring characters for the 
pharmacological mechanics as they likely act as carriers for drug 
delivery, release, activation modulators and, ultimately, drug 
targets.11,15-18 
Major drawbacks for cisplatin had emerged suddenly as it prompts 
severe side effects mainly because the drug blindly strikes both sick 
and healthy cells. Furthermore, many tumours exhibit either acute 
or acquired resistance towards this medicine as well as barely 1% of 
administered drug actually reaches its DNA target.11,15,19 This had 
shoved towards developing new Pt compounds but only a few 
(carboplatin and oxaliplatin are the most representative - Figure 1) 
have actually proven effective and eventually been approved.20,21 
Square-planar coordination geometry of Pt(II) is thought to be the 
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utmost limiting factor for Pt effectiveness.22 A brief gallery of 
representative platinum anticancer agents is reported in Figure 1. 
The success and limitations of Pt drugs have been driving forces 
towards probing new and diverse metals in cancer treatment. 
Ruthenium, palladium and gold-based compounds came next and 
the medicinal inorganic chemistry research branch has been 
progressively thriving since then, as the anti-tumour qualities of 
many other metals have been studied, including, iridium, osmium, 
cobalt, vanadium, copper and others.1,3,11,23-25 
 
Figure 1 – Chemical structures for the most representative Pt-based anticancer active drugs. 
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 Palladium and Gold 
Beyond platinum and among other metals tested in anticancer 
treatment, palladium and (even more) gold should deserve a much 
deeper discussion than this text is meant for. 
A palladium complex has been the first Pt alternative undergoing 
clinical trials against different solid tumours. Pd exhibits 
coordination and geometry likewise Pt but with a higher tendency 
to hydrolysis. Its complexes have been recorded cytotoxic towards 
a variety of cancers though no actual breakthroughs have been 
clinched in the search of cisplatin successor. For a more 
comprehensive insight please refer to.15,26-28 
The first and longstanding application of gold in modern medicine, 
the rheumatoid arthritis treatment, dates back to the 1930s and 
stayed as almost the sole gold medicinal usage until late XX century. 
Au(I) thiolates are the class forefathers whereas auranofin is 
probably the most famous modern successor, on duty since 1985.29 
Notwithstanding Au(I) complexes do have striking cytotoxicity 
against haemolymphatic cancers in-vitro, most of them arose severe 
cardiac threats and hence rejected for clinical trials.15 
Au(III) compounds are drawing lively research energies as they 
have been proved to be a good source of potential alternatives to 
cisplatin, mostly because resembling the Pt(II) d8 electronic 
configuration. In spite of structural similarities, Au(III)-based 
drugs act somehow differently from cisplatin, additionally showing 
a larger variety of DNA- or protein-binding chances, but 
inconsistent results achieved from different complexes contribute 
to puzzle the big picture of Au(III)-complexes action mechanisms.15 
Au(III) complexes also share a variety of cons with cisplatin when 
it comes to high toxicity, induced drug resistance, deficiency in 
cancer-cell specificity and limited bioavailability. 
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Anyhow a number of gold complexes, notably those based on 
thiocarbamates, have demonstrated to be worthy candidates for 
taking over from cisplatin as effective and non-toxic anticancer 
agents. Readers should refer to following references for further 
details.3,11,15,25,30,31  
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 Iridium 
No sooner had the Pt compounds been exploited than the d7 
element iridium, and its groupmate rhodium, had attracted the 
scientists interests as potential Pt alternative in cancer treatment, 
but it took longer to accelerate enough the Ir very slow aquation 
kinetic by ligand substitution to make its complexes actually 
bioactive.15,25,32 
Iridium complexes had shown effective in a range of biomedical 
applications such as protein and peptide labelling and sensing, 
cellular and tissue imaging and anticancer.32-40   
At the beginning, most efforts had been poured for Ir(I) complexes 
exhibiting square-planar geometry, as seen for cisplatin, but Ir(III) 
compounds have demonstrated effective and taken the scene, 
mostly as organo-iridium complexes.32 
Amid other metals, such as Mn, Fe, Co and Ru,41-43 iridium has 
shown effective as carbon monoxide-releasing molecules (CORMs) 
as well.43,44 
Carbon monoxide (CMO) has been recognized as a viable 
therapeutic molecule for an assortment of conditions and 
mechanisms (Figure 2) including cancer but, on the flip side, the 
very low binding selectivity the CMO has towards plenty of 
biomolecules can easily turn it into a poison rather than a remedy.45  
Here-hence the need for CORMs as it had been demonstrated that 
carbon monoxide release could realise selectively and modulated 
under certain conditions once bound to a metal.45,46 
The CMO release has been reported to occur in different ways 
according to the core metal and its ligands, including unmodulated 
thermal activation,47 simple hydrolysis in physiological buffers,47 
enzymatic catalysis,48,49 or by photo-activation.50,51 
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Anyhow, a rational development of CORMs passes through a 
comprehensive understanding of their pharmacological 
mechanisms. Therefore, the comprehension of the interaction of 
CORMs with biological macromolecules, mainly plasma proteins, 
cannot be left apart, but a few studies have taken this aspect into 
account by now.52-56 
This work will address for new insights on the interaction between 
a novel Ir-based CORM (IrCl5CO)43 and the bovine pancreatic 
ribonuclease A, a model protein system (see Chapter 6 – page 87).57 
 
 
Figure 2 - Biological effects of carbon monoxide delivered as a gas or as a CO-releasing molecule 
(CORM).52  
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 Ruthenium 
Ruthenium deserves a special mention in the metal-based drug file 
as its complexes are doubtless the most promising, interesting and 
studied all over the current inorganic chemotherapeutic scenario.15  
Ruthenium drugs as anti-tumour agents had been first tested by 
Clarke et al. but it took a while for Ru-drugs to find actual 
deployment since the first synthesised complexes suffered mainly 
from very low solubility.58-61  
Most of the early efforts have been put-in to solve this very issue 
and, albeit none of the complexes proposed has achieved to reach 
actual clinical usage as yet, two acclaimed complexes, namely 
†NAMI-A (New Anti-tumour Metastasis Inhibitor), and ‡KP1019, 
have both reached phase II in clinical trials showing remarkable 
performances.11,16,58,59,62 
A little more in detail, NAMI-A yet exhibits some curbs because of 
its sudden ligand swapping within minutes in aqueous 
environment at physiological pH and temperature.63,64 This makes 
NAMI-A nearly inactive towards primary cancers, whilst 
expressing appreciable anti-metastatic action.58,60,64,65 Consequently, 
it became clear that its activity could not relate directly to the 
nuclear DNA binding.66,67 Clues about the NAMI-A interaction 
with actin-type surface proteins68,69 and extracellular collagens 
matrix,70,71 both involved in well-known mobility frameworks of 
metastatic cells, suggest possible protein-mediated mechanisms to 
explain the anti-metastatic virtues of NAMI-A.64,68-73 
The KP1019 complex has been introduced at roughly the same time 
as NAMI-A but, on the contrary, it is much more stable in 
                                                      
†imidazolium trans-[tetrachloro-(S-dimethyl-sulfoxide)(1H-imidazole)ruthenate(III)]  
‡indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] 
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physiological conditions and shows more favourable cellular 
uptake kinetics than NAMI-A.23,24,74-76 
KP1019, and even more its derivative KP1339, are curiously and 
providentially completing what left uncovered by NAMI-A. It 
indeed possesses slight anti-metastatic activity but striking strength 
against primary cancers as well as towards some cisplatin-resistant 
tumours.4,58,74,77 
A number of studies have definitively casted off the paradigm of the 
exclusive interaction with DNA, bringing hints for diverse 
mechanisms of action mostly entailing Ru-protein dealings.72,73,78,79 
This prompted to broaden the knowledge about the underlying 
structural basis in the endeavour to mature the big picture of 
selective Ru-drug delivery and targeting.16-18,80 
Ruthenium-based drugs owe much of their success in the current 
anticancer panorama to the ease they access different oxidation 
states under physiological conditions.16,81 Ru(III) is the dominant 
and most stable form though marginally anticancer active and 
largely bound to blood-plasma proteins once administered, 
essentially acting as a prodrug form.4,58,64 In fact, its anti-tumour 
potential has been proven to rely on the reduction to Ru(II),61,82,83 
which is widely recognised to be the utmost anticancer-active 
ruthenium form.4,58,64 Ru(II), alike Ru(IV), can be promptly 
accessed in the presence of ordinary biological reducing or 
oxidising agents, particularly abundant within cancer cells 
environs.4,25,64,82-85 Hypotheses have been advanced for Ru(V) species 
within cells as well, but this stays controversial.58,86 
These alluring traits of the ruthenium redox chemistry resemble the 
“activation by reduction” theory that, first postulated for Pt(IV) 
complexes, has proven somewhat successful among the whole set 
of different strategies for selectively releasing and/or activating 
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higher oxidation state complexes that, accordingly, are to be 
referred to as prodrugs.64,82,87 
The bedrock for the edge that ruthenium has over Pt or Au is the 
octahedral geometry that its complexes exhibit (Ru(II) commonly 
have also piano-stool pseudo-octahedral geometry).58,88,89 The 
octahedral coordination geometry grants superior flexibility, meant 
in terms of chances for tuning their selective targeting and 
activation compared to Pt-complexes,30,59,73,81 i.e. by tweaking the 
valuable axial ligands for fine-tuning the steric, electronic and 
hence thermodynamic and kinetic properties of the complexes.15,64,73 
Ultimately, the aggregate of these features leads to a general lower 
toxicity compared to Pt compounds, though retaining an excellent 
in-vivo anticancer activity.16,90,91 
In spite of sparkling research activity, challenging issues remain. 
Developing selective targeting and activation is the foremost 
priority for addressing side effects and improving medicine 
effectiveness. Besides and surprisingly, the structures, speciation in 
biological environs, exact molecular targets and acting mechanisms 
have not yet been elucidated for a significant number of approved 
and in-development drugs either.16 A deeper insight into these 
pharmacokinetics and pharmacodynamics aspects may also lead to 
fresh and efficient drug-designs for treating a wider host of diseases 
yet not tackled. 
This text addresses for the investigation of some key physical 
chemical properties of AziRu, a novel Ru-based prodrug derived 
from NAMI-A (see Chapter 7 – page 107).  
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 Metal nanoparticles 
Nanoparticle research is nowadays a cutting-edge area of intense 
scientific efforts due to the huge pool of actual and potential 
applications in biomedical, optics, electronics, engineering and a 
variety of diverse fields. This comes from the large number of 
special properties compared to bulk material that the nanoparticles 
(NPs) exhibit. By far the most investigated nanoparticle systems are 
gold nanoparticles (AuNPs).92 Their properties tightly relate to size, 
shape, aggregation and local environ state (as a rule a thumb for 
each nanoscale system). 
Optical properties are the utmost apparent feature which depend 
mostly on size, shape and dielectric constant of the surrounding 
environ. AuNPs exhibit a distinctive size-dependent wine-red 
colour when sphere-shaped because of the Surface Plasmon 
Resonance (SPR) effect.92-94 SPR generates from the interaction 
between electromagnetic radiation of an appropriate wavelength 
and the metallic surface, resulting in an electric field on the 
nanoparticles surface that triggers the enhancement of the incident 
field by several magnitudes.93-96 
This huge magnification of the electric field adjoining the NPs (as 
well as rough metal surfaces) is the source of the sturdy 
enhancement in the Raman scattering cross-section known as 
Surface Enhanced Raman Scattering (SERS), first observed by 
Fleischman, back in 1974.92,97  
Because of these exceptional features, AuNPs found a rich variety 
of applications in industry, and progressively in consumer markets, 
in a large assortment of areas i.e. nano-catalysis, sensing, storage 
and computing devices, nano-devices, nano-labelling, bioimaging 
and therapeutic purposes.93,98-101 
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Medicinal and biotechnological applications greatly benefited from 
the  large AuNPs biocompatibility, which made of theme appealing, 
among other purposes, for anticancer intents.102-104 Furthermore, 
AuNPs have large and tuneable absorption in the near infrared 
(NIR) spectral region, where most of tissue components are nearly 
transparent, making of theme the perfect candidates for in-tissue 
sensing and photo-therapy.102-105 Indeed, the NIR-related 
photo-thermal effect have also been profitably exploited to 
selectively kill tumour cells in-vivo.92,93,106,107 
The very high AuNPs SERS allows to sniff out minute concentration 
and led to further advances in molecular detection: trace analysis of 
various organic compounds, biomolecules and even bacteria and 
viruses, antigens, carbohydrates, polluting agents, proteins and 
nucleic acids up to 10-9 M, and more.92,95,96,108-115 
AuNPs also exhibit very appealing catalytic properties e.g. can 
convert the highly toxic carbon monoxide (CMO) to the less 
troublesome carbon dioxide,116,117 catalyse hydrogenation 
processes,98 pesticides degradation118 or enhance visible light optical 
absorption within solar cells.98 
Interestingly, catalytic properties have been demonstrated to be 
size- and shape-dependent likewise optical features.98,119,120 
Efforts have been spent for developing high-yield hybrid catalytic 
systems made up by coupling AuNPs and enzymes either in 
solution or in crystalline state.121-124 
Herein I will discuss about new structural findings concerning these 
newly proposed catalytic hybrid systems (see Chapter 4 – page 61). 
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 Aims and Targets 
This brief introduction to the metallic world guided the reader 
through interesting spotlights that make the study of the interaction 
between either metal-ions and metal-nanoparticles with protein 
systems very appealing from a variety of perspectives. The 
anticancer purpose remains as the forefront due to its uncountable 
social impact. A deeper comprehension of key aspects driving the 
functioning of these systems may spring new interesting outlooks 
for the development of some alluring potential anticancer drugs. 
Besides metal-based drugs, the methodological approach herein 
adopted efficiently works also for studying metal-containing 
protein systems and it has been successfully deployed to enquire 
into the interaction between the Zn-containing protein human 
carbonic anhydrase II (hCAII) and some of its inhibitors (see 
Chapter 5 – page 73). 
This work is to be meant as consolidating the relatively novel and 
progressively spreading methodological approach named 
Raman-assisted Crystallography (RAC from now on), which 
combines strengths from Raman microspectroscopy and X-ray 
crystallography techniques for overriding their respective 
weaknesses, by securing structural and physical-chemical 
information for either metal-based drugs and metal-containing 
proteins. RAC has been deployed as pivotal tool besides a set of 
common spectroscopic techniques. 
X-ray crystallography stays as the golden standard for structural 
investigation providing nearly atomic resolution data though yet 
having some limitations. Raman microspectroscopy thus turns 
useful as a source of valuable data for integrating crystallographic 
records. 
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The synergy of these two techniques has been progressively thriving 
during the last decade and a brief introduction to the RAC concept 
and its applications, in addition to some theoretical pills about the 
two techniques it relies on, are discussed in the section to come. 
Detailed methodological and technical information are provided 
within each experimental section in the chapters to follow, whilst 
here is a brief summary of the investigated: 
• In chapter 2 early RAC experimental setup is proved by 
detecting Hg2+ insertion and its induced structural 
modifications within a single protein crystal. 
• In chapter 3 a combination of ultrahigh resolution X-ray 
data and online Raman spectroscopy for the 
characterisation of the X-ray induced photodamage on 
single protein crystal. 
• Chapter 4 confutes previous crystallographic evidences for 
the AuNPs co-crystallization within lysozyme crystals.  
• Chapter 5 addresses illustrates the disambiguation of the 
binding mode of a new carbonic anhydrase inhibitor via 
RAC. 
• Chapter 6 addresses for the Ir-based CORM binding to 
proteins and thereon CO release. 
• Chapters 7 and 8 discuss about the structural and 
physical-chemical characterisation of the selective 
reduction/release mechanism from proteins of a 
ruthenium-based prodrug, by means of RAC and 
electro-SERS. Part of these activities have been brought out 
during my stay at the TUB in Berlin. 
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 Raman-assisted 
Crystallography 
This section provides a brief introduction to the concepts beyond 
the experimental approach adopted in this thesis, yielding a brief 
and basic theoretical introduction to the techniques it relies on, 
redirecting to each experimental section for further detailed 
information. 
The Raman scattering phenomenon has been named after the 
Indian physicist who first had discovered the inelastic scattering of 
light phenomenon, back in 1928. 
It relies on the inelastic scattering of a small fraction of 
monochromatic light at frequencies determined by the structure of 
the molecule and the resulting scattered light can have either higher 
(Stokes scattering) or lower (anti-Stokes scattering) energy than the 
incident beam. 
Raman spectroscopy provides detailed vibrational information 
concerning the structure of molecules as the position and intensity 
of spectral features return the molecular structure and can be used 
to determine the chemical identity of the sample. 
Compared to other renowned spectroscopic technique, e.g. FT-IR, 
Raman spectroscopy diffusion had deeply suffered from the lack of 
highly bright light sources because of the very low signal-to-noise 
ratio it offers. The blossoming technologies of lasers, 
charge-coupled detectors and filters had significantly enlarged the 
horizons of this non-destructive, highly sensitive and informative 
vibrational spectroscopy across the fields of chemistry, biology, 
physics, geology, pharmacology, forensics, pharmaceuticals, 
materials science, cultural heritages and others.125   
Amid this large landscape of possibilities, from the standpoint of 
this work the foremost interest for deploying Raman spectroscopy 
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is the opportunity to obtain information-dense spectra of proteins. 
The perspective for a Raman characterization of proteins has been 
first drawn by Edsall back in 1938126 but 20 years had gone before 
the very first spectrum of lysozyme had been achieved.127 An actual 
structural interpretation could be advanced a dozen years later once 
Tobin,128 Lord and Yu129,130 provided the earliest laser-powered 
Raman spectra of proteins. The laser era, alongside the collection of 
Raman spectra from protein crystal, granted a fair increase in the 
signal-to-noise ratio allowing the first steps towards the 
Raman-based structural investigation of proteins. Resonance 
Raman (RR) spectroscopy came next, first on rhodopsin from 
bovine retina,131 then on metallo-proteins paving the way for the 
fruitful haemoprotein branch.132-135 It consists in the large 
enhancement of the Raman signals by using exciting wavelength in 
the absorption range of the sample.136 
Several Raman-active vibrational modes serves as fingerprints for 
the structural analysis of peptides at sub-atomic resolution as the 
precise wavenumbers of many bands strongly depend on inter- and 
intra- molecular effects e.g. peptide-bond angles and 
hydrogen-bonding patterns, permitting a sensitive interpretation 
of the secondary structure arrangement. 
The secondary structure interpretation mostly relies on the amide 
bands position and shape: nine normal modes are allowed for the 
amide band of proteins that are named A, B, and I to VII in order 
of decreasing wavenumber and reveal the main polypeptide chain 
structure regardless the contributions from side groups. 
The Amide A and B (from the NH stretching mode, around 3500 
and 3100 cm-1 respectively)137 are usually little informative as they 
both fall in the region of the Raman-active water region (ν1 OH 
stretching).137,138 
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The most informative amide I band (C=O stretching mode), almost 
entirely buried under the ν2 OH bending modes of water at IR 
analysis, is clear at Raman spectroscopy.139 On the contrary, the 
amide II band, from the N-H bending and the C-N stretching in the 
1480–1580 cm-1 range is barely Raman-active and usually of little 
relevance in the interpretation of complex spectra. Amide III band, 
1230-1330 cm-1, arises from the C-N stretching and from the N-H 
bending and represents a useful fingerprint for the secondary 
structure besides the amide I. The remaining amide bands (IV - 
OCN bending, V - out-of-plane NH bending, VI - out-of-plane 
C=O bending and VII - skeletal mode) exhibit very weak activity 
and are usually hidden by other spectral features from the amino 
acids side chains.138,139 
 
Figure 3 – Scheme of Amide I-III modes. 
In addition to the amide bands, many other spectral features 
referring to the amino acid side-chains are indeed clearly apparent. 
The side-chain vibrational modes of aromatic residues have been 
pin-pointed by Harada and Takeuchi.140 The Raman bands around 
1360 and 1340 cm-1 are known as the tryptophan doublet, and its 
relative ratio, I1360/I1340, reflects the hydrophobic/hydrophilic 
environments of the Trp residues.141 Another band around 880 cm-1 
is representative for the Trp and their environ.141 Two features at 
860 and 830 cm-1 are diagnostic for the tyrosine and their local 
microenvironment. The couple is known as the Tyr doublet and 
arises from the in-plane breathing of the and out-of-plane 
deformation modes.142 Raman spectroscopy is also very sensitive 
towards the sulphur-containing residues and their relative 
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conformations. In the low frequency region, the ggg conformations 
generates spectral features around 508-512 cm-1 whereas the tgg at 
523-528 cm-1 and the tgt at 540-545 cm-1.138 Sulphur-containing 
methionine residues can be detected within the range 700-725 cm-1 
but these are fairly unlinked from the conformation.138 
Raman spectroscopy is useful also for acquiring information related 
to the primary structure of proteins, e.g. to detect the 
selenio-methionine incorporation.143 It serves as a non-destructive 
and selective fingerprint for the tertiary structure as well. Indeed, 
Raman spectroscopy has been deployed to obtain information 
particularly related to the active site of enzymes.144,145 
Intermolecular interactions can be surveyed withal, like ligands 
binding or enzymatic catalytic processes.146,147 
Anyhow, although Raman spectra provide such a powerful 
information-dense data batch, when it comes to protein structure 
none compares to X-ray crystallography. Since the first 
haemoglobin and myoglobin structures have been Noble Prize 
awarded in 1962,148 the X-ray crystallography dominion remains 
uncontested and, to date, the Protein Data Bank accounts for some 
hundred twenty thousand crystallographic records.149 
Briefly, the X-rays radiation spans from 10 to 10-2 nanometres and 
the typical wavelength adopted for crystallography is around 1 Å 
(10-1 nm), which is on the scale of covalent chemical bonds and the 
radius of a single atom. Incident photons thus get elastically 
scattered by electrons in the atomic shells. Scattered photons mostly 
elide each other by 
destructive interference, a 
few specific scattering 
directions satisfy the 
Bragg’s condition150 
(Figure 4) and produce 
constructive interference 
Figure 4 – Scheme for the Bragg’s diffraction 
condition.  
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instead that translate into reflexes on the detector. Each reflex gets 
indexed using Miller indices (hkl), representative for the vector 
whose length equals the reciprocal of the distance between the 
Bragg’s planes that originated the reflex itself. 
The Fourier transform to follow re-enacts the relationship between 
each Miller’s vector with hkl coordinates and the electron density 
(σ) in the real space: !"#$ = 	 1( ) "#$ * +,-./ * 012+ "34#54$6"#$  
with V being the volume of the crystalline unit cell, α(hkl) the phase 
associated to the structure factor amplitude |F(hkl)|: this latter is 
experimentally measured while the phase is not, setting up the phase 
issue that can be addressed with different methods, described 
elsewhere.151-153 By iterative stages, the protein model structure gets 
refined at nearly atomic resolution giving unmatched structural 
details. Anyway, the final three-dimensional model, hence the 
information one can retrieve form it, suffers from technical and 
theoretical limitations as well as potential data misinterpretations, 
mostly depending on quality of the crystal. 
Resolution is usually the most limiting variable defining the 
impassable limit for the atomic coordinates, and for structure above 
1.2 Å it is virtually impossible to determine the coordinates for 
hydrogen atoms. Moreover, X-ray crystallography not always 
allows to unambiguous discern between atoms with close Z 
number, such as oxygen from nitrogen or even carbon, and their 
assignment within the electron-density maps are mostly deductive. 
As a consequence, the actual a certain degree of ambiguity 
challenges the crystallographer to a reasoned interpretation. Is that 
a water or a metal atom? The complexity arises as the number of 
deducible information lessen, for example in the interpretation of 
ligands and their interaction modes. 
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In addition to the intrinsic uncertainty of atom coordinates 
addressed by the resolution value, most of the proteins usually do 
not strictly comply to the ideal highly-ordered definition showing 
intrinsic disorder as some regions of the molecule may adopt 
different and sufficiently stable conformations in different copies of 
the molecule. Some protein domains, e.g. large loops and random 
coils segments, are so much intrinsically disordered that it is 
impossible to define any proper crystallographic model sometimes. 
Major advances in the chase of higher and higher resolution limits 
and data quality have been achieved by synchrotron light sources, 
which guarantee highly intense, collimate coherent radiation. 
Anyhow, this came with a trade off in terms of increased 
photodamage, a worrying crystallographic issue though 
cryo-cooling techniques partially addressed the problem.154 
Third and fourth generation synchrotron beam lines rapidly warp 
the diffractive capacity of the protein crystal resulting in two sort of 
damage even under cryo condition: global and specific. The former 
reveals through diffraction quality decay in terms of highest 
resolution shell loss, unit-cell volume expansion, reduction of the 
signal-to-noise ratio and increased mosaicity. On the contrary, 
specific damage concerns the electron density surrounding specific 
atoms and/or portions of the protein structure.155 
Disulphide bonds gets very rapidly distorted, reduced, and broken 
eventually, aspartates and glutamates are decarboxylated, 
methionine suffer for S-C cleavage and tyrosine may possibly, 
though yet disputed,155 lose their OH group.156-164 Utterly, these 
individual events may prompt severe global structural 
modifications and mislead the experimental interpretation.154,165,166 
The jointing limits and strengths of Raman spectroscopy and X-ray 
crystallography draws for a solid reciprocal supportive integration, 
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which has begun to establish in recent years as Raman-assisted 
crystallography (RAC).167 
Macromolecular crystals indeed provide very good conditions for 
efficient Raman protein spectra collection because of their very high 
protein concentration (can be assumed at an upper limit). As 
aforementioned and in addition to, Raman spectroscopy is 
relatively little affected by the solvent usually, and represent a very 
well suited complementary tool to X-ray crystallography. 
The Raman-assisted crystallography is being deployed for an 
increasing variety of purposes. It served for identifying 
intermediates of the reaction catalysed by the superoxide 
reductase,147 proving selenium-containing methionine 
incorporation prior anomalous scattering experiments,143 or for 
monitoring the ligand binding/release within the protein crystal 
and its modification.18,168,169
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2 
Spotting Hg2+ within 
protein crystals  
his section describes a simple yet very effective Raman-based 
approach to detect the insertion of mercury ions into cysteine pairs 
within protein single crystals, as a first step toward proving know-how, 
technical set-up a feasibility of the RAC approach. The method has been 
developed using bovine insulin as the model system by applying an 
effective mercuration protocol: a TCEP-induced disulphide bridges 
reduction within the crystal, is followed by an overnight reaction with a 
HgCl2 solution producing Hg-derivative crystals. Raman spectra collected 
on these derivative crystals, kept in the mother liquor, reveal a 
characteristic Raman band that has been assigned to a -S-Hg-S- bridge 
formation. This analysis provides Raman-based markers for the mercury 
binding to cysteines and further proves the reliability of the Raman-based 
approach for the detection of interacting metals with protein systems, as 
well as providing precise structural information as confirmed by 
comparison with X-ray clues.  
T 
A complex system that works is invariably found to have 
evolved from a simple system that worked. A complex 
system designed from scratch never works and cannot be 
patched up to make it work. You have to start over with a 
working simple system. 
-The Gall’s Law- 
“ 
“ 
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 Introduction 
Protein crystals distinguish themselves in the crystalline world 
because of their very high solvent content (up to 60%) compared to 
small molecule crystals, making of them gel-like rather than a 
classic solid, and must be constantly dunk in their mother liquor or 
will dissolve otherwise upon drying. 
Derivative protein crystals are prepared either via co-crystallization 
of protein and reactant or via reactant soaking from the mother 
liquor into the protein crystal through the large solvent-accessible 
channels within the solid phase. 
Metal binding to proteins is an open research field in 
crystallography and the adoption of microspectroscopic 
techniques, including Raman spectroscopy, are constantly thriving 
and spreading over this bio-structural research areas. 
Both inorganic170  and organic171  mercury compounds, such as Hg2+ 
ions, methyl- and ethyl- mercury,172 are known since long as toxic 
agents in several poisoning mechanisms e.g. alteration of cell 
membrane permeability,173 non-specific inhibition of several 
enzymes, synaptic transmission and neural fibre degeneration, 
nephrotoxicity, alteration of cholinergic neurotransmission 
functionalities, immuno-toxicity, and reduction of haemoglobin’s 
oxygen-carrying capacity.174 Finally, they are also likely 
carcinogenic, even though yet not completely demonstrated due to 
the need for long term data collections.175 
Mercury toxicity mechanisms essentially link up with two main 
types of actions: i) protein binding (enzymes, receptors, structural 
proteins etc.), and ii) interaction with nucleic acids.176,177 In 
particular, numerous toxic effects of both organic and inorganic 
mercury compounds are attributable to the capability of these 
 25 
substances of interacting in different ways with the side chains of 
protein residues, causing a number of effects. 
Among the many possible interactions of mercury compounds with 
protein atoms, the most common is through the binding with 
sulphur atoms of cysteines, resulting in relatively stable Hg-cysteine 
complexes. The formation of such complexes has been 
demonstrated to alter the protein folding seriously.177-179 
Valuable information on Hg2+ reactivity with amino acid side 
chains comes from fundamental bioinorganic studies, which had 
demonstrated the formation of +Hg-S-Cys and Cys-S-Hg-S-Cys 
complexes either, mostly depending on the proximity of the 
cysteines. On the other hand, because of the presence of the alkane 
chain, organic compounds do not form –S-Hg-S- bridges. For 
example, in the case of methylmercury, H3C–Hg–S–Cys forms are 
well known for the mammalian thioredoxin system.180 
Although Hg2+ preferentially reacts with –SH groups, it is known to 
react with different side chains as well. Evidences for the interaction 
of Hg2+ with histidine has been collected since 1950s. Because of the 
relationships between histidine and histamine, widely involved in 
local immune responses, Hg2+ poisoning triggers severe immune 
system diseases.179 Furthermore, oxygen atoms of Asp and Glu 
residues COO- groups are highly sensitive target towards mercury 
as the carboxyl group readily reacts with almost any mercury 
compound forming organo-mercury salts. Amide residues are 
known to have a key role in Hg–DNA binding181 and amide groups 
of amino acid residues are potential binding targets as well, thus 
making virtually any protein liable for mercury attack. 
Herein, the bovine insulin crystals have been adopted as model 
system. It differs from its human counterpart only in three amino 
acid residues, is composed by two polypeptide chains: chain A has 
21 amino acids and chain B has 30 amino acids. Two disulphide 
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bridges (between residues A7 and B7, and A20 and B19) covalently 
tether the chains. Moreover, chain A contains an internal 
disulphide bridge (between residues A6 and A11 - Figure 5). 
Notably, the position of these three disulphide bonds is invariant in 
mammalian forms of insulin making of it perfectly fitting for the 
extent of this work i.e. the definition of a simple practical protocol 
for detecting the Hg2+ insertion into protein crystals via Raman 
microscopy. 
  
Figure 5 - Cartoon representation of the bovine insulin structure (PDB code 1ZEH), chain A is 
dark purple, chain B green. Disulphide bridges are also shown as balls and sticks. 
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 Experimental 
Crystals of bovine insulin had been grown using the vapour 
diffusion hanging drop method. Crystallization conditions had 
been optimised starting from condition reported in literature for 
the human variant.182 Very well-shaped but tiny crystals grew in 
these conditions (≤30 μm) but much larger crystals had been 
successfully obtained by “poisoning” with Tacsimate, which slows 
down the crystallization process and therefore prompts a noticeable 
increase of crystal size (>100 μm). 
Optimal crystallisation condition had been identified and best 
crystals have been obtained from crystallisation solutions 
containing 3% v/v acetone, 5·10-2 mol L-1 sodium citrate at pH 6.3, 
10-3 mol L-1 ZnCl2, 5% v/v Tacsimate at pH 7.0, all at a 1:1 protein-
to-reservoir ratio in 1 μL drops and using an initial bovine insulin 
concentration of 0.5 mg mL-1. 
These crystals diffracted X-rays at about 2 Å resolution and have a 
solvent content as high as 35%.183 
A two-step mercuration protocol has been adopted: first, the S-S 
bridges reduction to the highly reactive free –SH thiol groups by 
using a 8·10-2 mol L-1 solution of tris[2-carboxyethyl]phosphine 
chloride (TCEP) as reducing agent, whose pH had been adjusted to 
7.0 by NaOH addition, as previously reported.182 Reduced crystals 
had been handled and stored in an oxygen-free atmosphere 
(nitrogen box at 1 ppm O2) in order to prevent  re-oxidation. 
Crystals had been soaked overnight in a saturated aqueous solution 
of HgCl2 and 2·10-2 mol L-1 sodium citrate at pH 6.3. 
Raman data had been collected using a commercial JASCO 
NRS-3100 Raman microscope system and either a 514 nm and 647 
nm laser lines from Ar+ and Kr+ tubes, respectively. Laser power at 
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the sample has been kept as low as 1 mW to keep any chance of 
photo-dissociation phenomenon out. 
Raman spectra acquired for bovine native insulin crystals, 
TCEP-reduced and upon Hg2+-soaked crystals are reported in 
Figure 6 (see below). To account for possible background 
interferences, the spectrum of the mother Raman spectra of the 
mother liquor are also reported. 
The prominent protein features include the Amide I band located 
at around 1659 cm-1, which is a signature of the α-helix insulin 
secondary structure184  and a 1680 cm-1 shoulder related to the 
ß-sheet secondary structure,182 the CH2/CH3 bending vibration at 
1448 cm-1, Amide III in various conformations at 1268 and 
1207 cm-1, C–N stretching at 1026, 1058, 1090, 1123 and 1154 cm-1, 
ring vibrations of the phenylalanine moiety at around 1000 cm-1, 
and a prominent peak at 508 cm-1 assigned to the disulphide S-S 
stretching mode. Deepening, the peak at 508 cm-1 relates to the 
gauche–gauche–gauche (ggg) conformation of the three torsional 
angles in the C-S-S-C groups, according to PDB entries 2A3G and 
4E7T and literature.185 
It is worth noting that the initially well-diffracting insulin crystals 
become totally disordered upon TCEP reduction (data not 
reported). Raman analysis clearly shows the reason for such a 
tremendous drop of crystal quality since, upon the addition of 
TCEP, the amide bands are replaced by a single ß-sheet marker 
band at 1673 cm-1. This spectral change is assigned to an α-helix to 
ß-sheet transition occurring upon reduction of the disulphide 
bridges, in agreement with earlier reports from human insulin.182 
Concomitant with this secondary structure transition, the 508 cm-1 
band, clearly visible in the native crystal spectrum, becomes 
featureless in the reduced form, consistently with the S–S reduction 
to SH groups. 
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Upon Hg2+ soaking, the Amide I band at 1673 cm-1 is still present, 
indicating that mercuration does not affect the secondary structure, 
but a new very intense spectral feature appears at 335 cm-1 
(Figure 6). This band has been assigned to the -S-Hg-S- stretching, 
in agreement with previous studies performed on cysteine crystals 
and solutions, where the -S-Hg-S- mode has been reported to be at 
334 cm-1,186 and on various mercapto-compounds, where 
the -S-Hg-S- mode has been reported to occur in the range 
290-390  cm-1.187 
This study is a valuable reference for Hg2+ binding to two Cys 
residues within a protein crystal. The 335 cm-1 Raman band is 
detectable with ease even using low laser power, as in this work to 
reduce any risk of photo-dissociation, because this band 
characterises for a very high intensity, remarkably comparable to 
Amide I band arising from the contribution of fifty amide bonds 
Figure 6 - Raman spectra of bovine insulin crystals. In the native insulin spectrum, a clear 
band at 508 cm-1, referred to S-S stretching, and a band at 1659 cm-1, related to an α-helix 
Amide I, are present. Because of the reduction of S-S bridges to SH groups, TCEP addition 
causes the disappearance of the 508 cm 1 band in the corresponding spectrum. In both TCEP 
and Hg2+ soaked insulin spectra, a single ß sheet related band at 1673 cm-1 is observed, due 
to an a-helix to b-sheet transition. A band at 796 cm 1 is visible only in the TCEP reduced 
spectrum and is likely due to TCEP itself. The spectrum of the precipitating solution, where 
the crystal is always kept, is also reported as ‘‘mother liquor’’. 
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whereas only three –S-Hg-S- bridges can be formed per insulin 
molecule. The high Raman intensity of the -S-Hg-S- band probably 
relates to the presence of the highly polarisable heavy atoms Hg and 
S, hence triggering very high Raman cross-sections confirming 
Raman spectroscopy as a very sensitive technique for the detection 
of mercury binding, even for a low Hg2+/residues ratio, bearing in 
mind the very low mean content of Cys residues in proteins, as low 
as 3%.188 
Two different laser lines had been deployed (514 and 647 nm) to 
rule out line-related dissociation phenomena (Figure 7). Anyhow, 
the spectra obtained by exciting with 514 and 647 nm are extremely 
similar as they both show the same very intense band at 335 cm-1. 
However, it should be stressed that this Raman marker is likely to 
apply only to -S-Hg-S- bridges, and that specific markers for free 
SH groups producing S-Hg+ species need further investigation. No 
additional bands, potentially due to different Hg2+ binding modes, 
had been observed. 
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Figure 7 - Comparison of Raman spectra of Hg2+ soaked crystals obtained by using the 
514 nm laser line (upper curve), and the 647 nm laser line (lower curve). No appreciable 
difference is observed. In agreement with previous results, the -S-Hg-S- band at 335 cm-1 
is present in both spectra with almost the same intensity. 
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 Conclusions 
This Raman microspectroscopy study on bovine insulin single 
crystals provides simple and effective mercuration protocol via 
prior TCEP-induced reduction of disulphide bonds. It also 
provides a sensitive experimental method to detect Hg2+ binding 
into cysteine pairs by recognising a very strong Raman band around 
335 cm-1 as a marker for -S-Hg-S- bridge formation. 
Further application of such procedure to free cysteines could be of 
interest for the preparation of isomorphous derivative crystals, 
often used in protein crystallography. 
At last, the crystallographic findings on spoiling of the crystal 
diffracting power upon reduction could be explained trough 
Raman spectroscopy, which gave evidences for the 7 → 9 
transition. 
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3 
Rac for Photodamage 
Detection 
…and though the light itself cannot even sketch up a crystal, as sure 
as death can destroy it. And we had lit up a crystal to cast light on 
the highly relevant, yet not completely established mechanisms of 
X-ray radiation damage on protein structure. This section addresses 
for the innovative adoption of Raman microspectrophotometry to 
follow the X-ray induced chemical modifications on the structure of 
the model protein bovine pancreatic ribonuclease (RNase A). The 
combination of dose-dependent Raman spectra and ultrahigh 
resolution (eight structures between 0.85 and 1.17 Å) allowed to the 
direct observation of several radiation damage events, including 
covalent bond breakages and radical species formation. This work 
provides relevant qualitative and quantitative results for a deeper 
understanding of the X-ray induced photodamage on single protein 
crystals, as well as Raman markers for its detection, possibly paving 
the way for a novel effective supportive method for X-ray data 
collection at synchrotron beam lines. 
“ ...light creates, light preserves, 
light destroys… 
-PJ Bailey, Festus- „ 
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 Introduction  
Major advances in the chase of higher and higher crystallographic 
resolution limits and data quality have been achieved by 
synchrotron light sources, which guarantee highly intense, 
collimate coherent radiation. Anyhow, this came with a trade off in 
terms of increased photodamage, a worrying crystallographic issue 
even though cryo-cooling techniques partially addressed the 
problem. For decades, structural changes induced by the radiation 
damages have been unrecognized but, once systematic studies have 
been performed, it has been shown how these events may affect the 
process of structural solution and the quality of the refined models. 
X-ray induced photodamage is a phenomenon caused mainly by a) 
the direct interaction between molecules in the crystal and the beam 
and b) the reactivity of radicals formed and propagated throughout 
the crystal. Two distinct indicators of damage as a function of dose 
have been identified in terms of global and specific damage.189 The 
former results in a loss of the measured reflections at highest 
resolution shells, decrease of the I/σ ratio, variation of unit-cell 
volume, increase of the Rmerge or Rsym values, which measure the 
internal consistency of X-ray diffraction data, increase of the 
Wilson B-value for the data and of atomic displacement parameters 
(B-factors) of the atoms in the refined model, rotation of the 
molecule within the unit cell and often an increase in crystal 
mosaicity. Specific damages include the appearance in solved 
structures of artefacts possibly affecting the interpretation of 
protein biological functions,190,191 like side-chain structural and 
chemical modifications, disulphide bond breakage 
ionization,159,160,192,193 metal reduction,194 ligand photodissociation.195 
Raman spectra of a protein represent molecular normal modes of 
vibration and can be used as a sensitive, non-destructive and 
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selective fingerprint for protein primary,196 secondary,138 and 
tertiary structure especially related to active sites,144,197 of 
intermolecular interactions and dynamics e.g. ligand binding and 
enzyme reactions.147,198 Coupled with X-ray crystallography, Raman 
microscopy can yield subtle in-crystallo information about the 
status of chemical events that occur in the crystal, including X-ray 
induced chemical modifications.55,168,195,196,199,200 Few examples of 
Raman microscopy detection of radiation damages have been 
published: these studies mainly focus on Br dissociation from 
DNA201 and disulphide bridge reduction.199 On the basis of this 
work, a mechanism of disulphide bridge repair has been also 
proposed.199 This joint approach has been also adopted for assessing 
the structural bases for a transient X-ray induced photo-bleaching 
in a green fluorescent protein.202 In 2013, the first Raman-assisted 
crystallographic evidence of the X-ray induced 
NO-photodissociation at a 3rd generation synchrotron (Swiss Light 
Source) has been reported.195  
Herein we use a combined crystallographic-Raman microscopy 
experiment to address the effect of an increasing radiation dose on 
the structure of the model protein bovine pancreatic ribonuclease 
(RNase A), in a cryo-cooled crystal. The section provides the 
Raman markers of photodamage, including methionine 
demethylation and decarboxylation of Asp/Glu residues. RNase A 
has been chosen as subject of our study since it has been used as a 
model protein in a number of different fields,203 including folding,204 
protein synthesis,205 enzymology,206 protein aggregation207 and 
protein metalation17,208-210 and has already been used to study the 
effects of X-ray dose on protein structure (PDB code 2BLP);211 it is 
commercially available at high purity and has small size 
(124 residues). The protein contains four disulphide bridges, no Trp 
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residues and its crystals diffract at ultrahigh resolution (between 
0.85 and 1.17 Å) even after extensive damages have occurred.  
This work is particularly addressed to those analytical applications 
in which Raman microspectroscopy assists X-ray crystallography.212 
Currently, several facilities allocate Raman microspectroscopy 
online with X-ray beamlines. Ultimately, herein a Raman-based 
protocol of X-ray induced photodamage is proposed, whose 
spectral assignments have been supported by ultra-high resolution 
crystallographic data collected at different X-ray dose. 
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 Methods 
3.2.1 RNase A Crystallization  
RNase A crystals have been prepared as previously described.213-215 
Briefly, lyophilized protein was dissolved in 20 mM sodium citrate 
pH 5.3 and used at a concentration of 30 mg/mL. The protein was 
inserted into glass capillaries, frozen at -20 °C to obtain a clear 
interface where 10 µl precipitating solution of 99.9% isopropanol 
was loaded. For cryo-protection, a crystal has been transferred to a 
solution containing 60% isopropanol, 20 mM sodium citrate buffer 
pH 5.3 and 15 % (v/v) glycerol and kept there for one minute. 
3.2.2 X-ray data collection and refinement 
Diffraction data on a single crystal were collected at the PXII 
beamline of Swiss Light Source (SLS) at eight different X-ray doses, 
i.e. between 2 and 24 MGy. Data collection statistics are reported in 
Table 2. The X-ray dose has been evaluated by using the software 
RADDOSE.216 The crystal diffracts at ultrahigh resolution (0.85 Å) 
and even when it receives a dose of 24 MGy, a complete data set has 
been collected at quasi-atomic resolution (1.17 Å). All data sets 
have been collected at 100 K using glycerol as cryo-protectant and 
processed with the HKL-2000 program suite.217 The refinements 
have been performed using SHELX-L.218 The structures 
anisotropically refine to values of Rfactor and Rfree in the range 0.09-
0.16 and 0.12-0.23 respectively. Details on refinements statistics are 
reported in Table 1.  
Radiation damage has been identified by inspecting the 2Fo-Fc, 
Fo-Fc and Fo-Fo electron density maps and calculating both Bdamage 
and Beffective, as recently reported by Garman and coworkers.219,220 
Bdamage  and Beffective,219 have been evaluated using both models refined 
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isotropically and anisotropically. When multiple conformations of 
a residue are present, they had been replaced by the highest  
occupancy conformation. 
 
 
Table 1 – Refinement statistics. Values in brackets refer to the highest resolution shell. Dose 2	 5	 8	 11	 14	 17	 20	 24	Resolution	(Å) 50[0.85]	 50[0.85]	 50[0.92]	 50[0.92]	 50[1.02]	 50[1.02]	 50[1.08]	 50[1.17]	Working	set	(N.) 74099	 77419	 64628	 59671	 47263	 41368	 30341	 23647	Test	set	(N.) 3888	 4106	 3415	 3131	 2455	 2165	 1559	 1251	Rfactor	(%)	 11.61	 9.77	 10.60	 11.13	 13.18	 14.01	 15.00	 16.11	Rfree	(%)	 14.98	 12.22	 13.63	 14.10	 16.53	 17.80	 21.52	 23.14	Rall	(%)	 12.14	 10.28	 10.89	 11.66	 13.45	 14.56	 16.09	 17.34	Non-hydrogen	atoms	(N.)	 1377	 1390	 1398	 1351	 1345	 1303	 1301	 1195	Mean	B-value	(Å2)	 15.57	 15.28	 16.74	 17.09	 19.17	 19.13	 21.02	 19.16	Ramachandran	statistics	Favoured	(%)	 98.4	 98.4	 97.5	 97.5	 97.5	 97.5	 97.5	 97.5	Allowed	(%)	 1.6	 1.6	 2.5	 2.5	 2.5	 2.5	 2.5	 2.5	Outliners	(%)	 0	 0	 0	 0	 0	 0	 0	 0	
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Table 2 - Data collection statistics of RNase A crystal at different X-ray dose. Values in brackets refer to the highest resolution shell. Dose	(MGy)	 2	 5	 8	 11	 14	 17	 20	 24	Space	Group	 p21	 p21	 p21	 p21	 p21	 p21	 p21	 p21	a	(Å)	 29.12	 29.16	 29.18	 29.21	 29.24	 29.25	 29.25	 29.26	b	(Å)	 37.97	 37.96	 38.04	 38.06	 38.09	 38.10	 38.09	 38.09	c	(Å)	 52.54	 52.72	 52.65	 52.72	 52.77	 52.80	 52.82	 52.82	α	(°)	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	β	(°)	 105.83	 105.80	 105.85	 105.88	 105.88	 105.89	 105.91	 105.91	γ	(°)	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	 90.00	Cell	Volume	(Å3)	 55900.2	 56151.7	 56221.5	 56390.3	 56516.0	 56580.8	 56614.6	 56600.7	Res.	limits	(Å)	 50-0.85	[0.88-0.85]	 50-0.85	[0.88-0.85]	 50-0.92	[0.95-0.92]	 50-0.92	[0.95-0.92]	 50-1.02	[1.06-1.02]	 50-1.02	[1.06-1.02]	 50-1.08	[1.12-1.08]	 50-1.17	[1.21-1.17]	Observations	 297362	 314305	 496316	 335098	 363201	 183087	 136313	 102155	Unique	observations	 92774	[8302]	 95598	[9346]	 76213	[7459]	 73777	[7198]	 54830	[5380]	 51404	[4981]	 41153	[4029]	 32132	[3153]	Completeness	(%)	 96.0	[86.2]	 97.8	[95.9]	 98.7	[97.4]	 96.2	[94.2]	 98.9	[97.7]	 91.9	[89.6]	 88.7	[87.6]	 88.1	[86.5]	Average	multiplicity	 3.2	[2.6]	 3.3	[3.2]	 6.5	[6.7]	 4.5	[4.6]	 6.6	[6.4]	 3.6	[3.4]	 3.3	[3.3]	 3.2	[3.1]	Rmerge	(%)	 0.067	[0.387]	 0.047	[0.353]	 0.075	[0.440]	 0.050	[0.471]	 0.094	[0.451]	 0.056	[0.431]	 0.07	[0.57]	 0.07	[0.47]	Mosaicity	 0.304	 0.335	 0.356	 0.396	 0.437	 0.436	 0.461	 0.471	I\σ	 8.3	[2.2]	 38.7	[2.5]	 11.25	[3.89]	 9.89	[2.53]	 10.15	[4.29]	 8.65	[2.47]	 8.12	[2.48]	 7.90 [2.29]	
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3.2.3 On line Raman microscopy 
To precisely follow the progress of X-ray-induced structural 
damage on crystalline RNase A, Raman spectra have been collected 
prior and after each X-ray diffraction data collection, restoring each 
time the same crystal orientation, using an on-line Raman 
spectrometer setup, the upgraded version of the as previously 
described system.221 The spectra have been recorded using 785 nm 
laser light excitation.  
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 Results and discussion 
3.3.1 Raman microscopy 
X-ray diffraction data collection assisted by online Raman 
acquisition, prior and after data collection, have been performed. 
Non-resonant Raman spectra of RNase A before and after eight 
successive data set are shown in Figures 8 and 9 whereas details are 
reported in each residue-specific section (see below). The high 
signal-to-noise ratio of the spectra originates from the high protein 
concentration in the crystal, the low solvent content, and the 
cryogenic temperature (100 K). The spectra display a series of bands 
that, based on previous assignments,130,222 report on vibrational 
modes associated with disulphide bonds (522 cm−1), methionine 
(665 and 724 cm−1), acidic residues (Glu and Asp, 1410 cm−1), as 
well as backbone amide bonds (amide I band around 1650 cm−1, not 
shown). At increasing adsorbed dose, by comparing successive 
Raman spectra (prior and after X-ray exposure), multiple Raman 
markers indicate the occurrence of photochemical events. Indeed, 
the intensity of several Raman bands associated to the 
aforementioned side chains decrease, while novel Raman bands 
appear possibly due to the formation of photoproducts. Some 
Raman bands from residues expected to be unaffected (e.g. the band 
at 1007 cm-1 arising from the angular bending of the Phe ring),223 
shows to be actually dose-independent and hence taken as internal 
quantitative standard for spectral normalisation. Amide band for 
all the collected spectra are invariably at 1650 cm-1 (data not 
shown), coherently with no change in the secondary structure as 
confirmed by electron density maps. Sections 3.3 reports on how 
these photochemical damages can be associated with the breakage 
of disulphide bonds, decarboxylation of acid residues (Asp and Glu 
and C-terminus), and breakage of covalent C-S bonds in Met. X-ray 
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induced modification via Raman microscopy, and in terms of 
ultrahigh resolution crystallography. 
A possible involvement of Tyr side chains appears unlikely, since 
electron density maps do not indicate significant modifications of 
the side chain of Tyr residues, in agreement with data by 
Gerstel et al.219 
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Figure 8 - Low frequency non-resonant Raman spectra of RNase A crystals as function of absorbed X-ray dose. Excitation line is 785 nm (10 mW at the sample), exposure 
time 120 s. Spectral resolution 8 cm-1. Raman spectra are normalised with Phe signal at 1007 cm-1 as a reference.  
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Figure 9 - Medium frequency non-resonant Raman spectra of RNase A crystals as a function of absorbed X-ray dose. Excitation line is 785 nm (10 mW at the sample), 
exposure time 120 s. Spectral resolution 8 cm-1. Raman spectra are normalised towards Phe signal at 1007 cm-1.
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3.3.1.1 Disulphide bonds 
Raman band at 522 cm-1, typically assigned to -S-S- stretching in a 
ggt conformation,224 decreases as dose arises (Figure 10) suggesting 
the disulphide bond breakage. Raman-assisted crystallography 
breakage of disulphide bridge has been already characterized in 
previous works.199  
Figure 10 - Detail for the rapidly decreasing band at 522 cm-1 related to the –S-S- modes of 
disulphide bridges. 
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3.3.1.2 Aspartic and Glutamic residues 
Both Asp and Glu residues are expected to suffer for 
decarboxylation as dose arises159,160,162,193 leading to CO2 release 
eventually. Raman spectra do highlight the decarboxylation event 
occurring for both Asp and Glu residues (Figure 11): a fast 
decreasing band (disappearance over 14 MGy) at 1410 cm-1 has 
been assigned to -CO2- groups, whereas two appearing bands at 
1275 and 1385 cm-1 possibly refer to the CO2 related vibrations 
(lower and upper Fermi dyad band, respectively). The arising 1385 
cm-1 band has been interpreted as relating to the •CH3 
photoproducts. This band can be used as diagnostic of Asp and Glu 
photodamage, (only) when it appears in combination with the 1275 
cm-1 feature. Otherwise it can refer to the demethylation of Met 
residues (see below). 
Figure 11 – Medium frequency non-resonant Raman spectra 
showing the decrease of the 1410 cm-1 band from Asp/Glu -CO2- 
terminal groups and two rising bands at 1275 and 1385 cm-1 from 
the Fermi’s dyad of CO2. 
 47 
3.3.1.3 Methionine residues 
The -C-S-CH3 group of methionine is expected to be a high 
sensitive photodamage target according to previous remarks.163,164,225 
In the low-frequency region, three bands have been assigned to 
methionine-related photodamage events: two fading-out features at 
665 and 724 cm-1 respectively, and a new rising band at 601 cm-1 
(Figure 12). According to Culka et al.226 the 665 and 724 cm-1 bands 
have been assigned to –C-S- stretching modes of Met. The slow 
reduction of these bands suggests the rupture of CG-SD and SD-CE 
bond within the Met side chains, as observed from electron 
densities (see below, Figure 21). The 601 cm-1 arising band over 17 
MGy has been assigned to an out-of-plane deformation of •CH3 
radicals, according to literature.227 In the medium-frequency 
region, Raman spectra show a clearly arising band at 1385 cm-1 
Figure 12 - Low frequency non-resonant Raman spectra showing 
a new rising band at 601 cm-1 assigned to •CH3 radicals 
formation and two fading-out bands at 665 and 724 cm-1 
diagnostic for –C-S- stretching modes of methionines. 
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which has been assigned to in-plane modes of •CH3 radicals.227 The 
appearance of the two features at 601 and 1385 cm-1 can be assumed 
as markers for photodamage affecting methionine. 
3.3.2 X-ray crystallography 
The eight crystal structures have the same overall secondary 
structure but a high number of tertiary structure modifications are 
clearly apparent. To follow, this work addresses for both the global 
and specific damage events by analysing electron-density maps, 
global crystallographic parameter, atom occupancy factors and the 
recently defined Beffective and Bdamage  towards the arising X-ray dose 
elsewhere defined (see 3.3.2 – page 48).219 
3.3.2.1 Global indicators 
Traditional parameters used to describe radiation damage in a 
protein crystal are diffraction limit, unit cell volume, crystal 
mosaicity and I/σ(I) ratio. RNase A crystals had diffracted at 
quasi-atomic resolution even once exposed to 24 MGy, indicating 
this system to be assuredly “X-ray proof”. However, analysis of the 
global parameters for successive data collections reported in 
Figures 13-15 clearly indicate a significant damage. In fact, an A	 B	
Figure 13 - A) Normalised cell volume (Å3) and B) mosaicity towards arising absorbed dose. 
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increase in the unit cell volume normalised to the cell volume of the 
first data set (Figure 13A), an increase in the crystal mosaicity 
(Figure 13B) and Rmerge Figure 14 and a decrease in I/σ(I) (Figure 15) 
indisputably indicate the photodamage occurrence.  
 
Figure 14 - Rmerge trends as function of arising dose for all of the eight data collections. 
 
Figure 15 - Signal to noise ratio as a function of resolution (Å) for each dataset. 
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3.3.2.2 Specific damage 
The parameters that were used to identify and quantify specific 
radiation damage are numerous. B-factors and relative isotropic 
B-factors can be certainly used to follow the progression of damage 
of groups of atoms within a protein structure, but they cannot be 
used to compare results obtained using different proteins. Recently, 
novel general parameters have been proposed: Bdamage, which is 
defined as the B-factor of an atom x, normalized to the average 
value obtained for all atoms in a packing density environment 
similar to that of the atom x, and Beffective that Garman and 
co-workers calculate using non-H atoms and isotropic B-factors.219 
Taking advantage from our well-refined atomic resolution 
structures, the more informative anisotropic B-factor have been 
used and their distribution and value as function of dose have been 
evaluated. As a comparison, isotropic B-factors have been also used 
not remarking decisive differences (data not shown). 
As expected and in agreement with Raman data, analyses of 
Occupancy factors, Bdamage and Beffective had allowed to the detailed 
identification of specific damage occurring at Met, Asp and Glu side 
chains of RNase A, as well as on its C-terminal Val. More in detail, 
the ultrahigh resolution data allowed for a precise estimate of 
occupancy factors as function of dose whose trends clearly increase 
but for Met29, Figure 16. Coherently, Beffective and Bdamage parameters 
both increase as dose grows (Figures 17 and 18). 
The -CO2- group of all Asp and Glu residues in our structures are 
liable to specific radiation damage. Analysing the electron-density 
maps reported in Figures 19-22, decarboxylation is evidenced for 
both Asp and Glu residues. Interesting, electron density maps also 
reveal CO2 loss from the C-terminal carboxylate Figure 22.  
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Regarding the Met side chains, data reveal a clear reduction of 
electron density around CE atom of, up to the complete 
disappearance of density over the 11 MGy threshold (Figure 21) 
for Met29. At a deeper inspection, the Met side chain electron 
density maps also show a less pronounced yet decreasing trend for 
the CD atom compared to CE atom. This should indicate that 
radiation damage leads to both •CH3 and, less abundant, •SCH3 free 
radicals. Generally speaking, such highly reactive species are likely 
to diffuse throughout the crystal affecting other chemical groups, or 
Figure 16 - Occupancy trends for damaged groups as a function of the arising dose (between 2 
and 24 MGy), normalised using the lowest dose dataset (2 MGy) as reference. For Glu and Asp 
residues the mean occupancy value of their CO2 terminal groups is reported. Met panel reports 
the occupancy trends for SD whereas SG is reported for Cys residues. Val124 trend refers to the 
C-terminal CO2 tail mean occupancy. 
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may rapidly back-react possibly explaining the persistent sulphur 
density.  
As a final comment, the rupture of disulphide bridge has been 
commonly found in radiation damage studies and according to 
Raman spectra the disulphide bridges are the most sensitive groups 
of RNase A. Refinement of occupancy factors of the side chain 
atoms of Cys suggests that free Cys are present in a very small 
amount (<15%) in our structures. These data suggest that the 
mechanism of S-S bond repair proposed by Carpentier et al.199 is 
probably operative also in this case. 
 
Figure 17 - Beffective trends for damaged groups as a function of the arising dose (between 2 and 24 
MGy), normalised towards the lowest dose dataset (2 MGy). Beff are calculated as the ratio between 
the mean B value of the affected group and the average of all non-hydrogen and non-solvent atoms 
in the structure. For multi-conformation residues, only the highest occupancy conformation has 
been taken into account. 
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Figure 18 - Bdamage trends for damaged groups as a function of the arising dose (between 2 and 24 
MGy), nomalised towards the lowest dose dataset (2 MGy). Bdam are calculated as the ratio between 
the mean B value of the affected group and the average of all non-hydrogen atoms within a radius 
of 6 Å. B-values have been refined anisotropically by fixing to 1.00 the occupancy of the highest 
occupancy alternate conformation where present. 
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Figure 19 - Specific structural damage suffered by Asp38 side chain within a cryo-cooled crystal 
of RNase A during sequential dataset collections at the SpectroLab PX12 beamline - SLS. For a 
meaningful comparison between maps computed from different datasets, each map has been 
normalised using the 2 MGy Cα density as reference, that is electron density maps for each 
analysed residue have been scaled at the same electrons per Å3 level of as the α-carbon of the 
corresponding 2 MGy map residue. 
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Figure 20 - Specific structural damage suffered by Glu111 side chain within a cryo-cooled crystal 
of RNase A during sequential dataset collections at the SpectroLab PX12 beamline - SLS. For a 
meaningful comparison between maps computed from different datasets, each map has been 
normalised using the 2 MGy Cα density as reference, that is electron density maps for each 
analysed residue have been scaled at the same electrons per Å3 level of as the α-carbon of the 
corresponding 2 MGy map residue. 
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Figure 21 - Specific structural damage suffered by Met29 side chain within a cryo-cooled crystal 
of RNase A during sequential dataset collections at the SpectroLab PX12 beamline - SLS. For a 
meaningful comparison between maps computed from different datasets, each map has been 
normalised using the 2 MGy Cα density as reference, that is electron density maps for each 
analysed residue have been scaled at the same electrons per Å3 level of as the α-carbon of the 
corresponding 2 MGy map residue. 
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Figure 22 - Specific structural damage suffered by the C-terminal of Val124 carboxylate within 
a cryo-cooled crystal of RNase A during sequential dataset collections at the SpectroLab PX12 
beamline - SLS. For a meaningful comparison between maps computed from different datasets, 
each map has been normalised using the 2 MGy Cα density as reference, that is electron density 
maps for each analysed residue have been scaled at the same electrons per Å3 level of as the α-
carbon of the corresponding 2 MGy map residue. 
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 Conclusions 
This study is among the trailblazing examples of Raman-assisted 
crystallography study for the evaluation of radiation damage in 
proteins and surely the very first providing:  
I. Raman markers for the Asp/Glu decarboxylation and C-S 
breakages in Met residues. 
II. Combines Raman microscopy with ultrahigh resolution 
data. 
The aggregate of these findings points out the strong agreement 
with crystallographic data as appreciable from the analysis of global 
and specific damage indicators, including the decarboxylation of 
Asp and Glu side chains, decarboxylation of the C-terminal tail, 
breakage of S-C and S-S bonds (that are likely re-formed in most 
cases). Ultimately, this combined crystallographic and 
spectroscopic method has provided an effective experimental 
protocol for the in-situ detection of the ongoing radiation damage 
in cryo-cooled protein crystals via Raman microscopy.  
It could trace the path for better and proper planning of X-ray data 
collections, that is, minimizing the adsorbed dose while 
maximizing the information that can be obtained from 
macromolecular crystals acquiring the highest possible resolution 
data compliant with the absence of artefacts. 
Mindful of these findings, particularly during synchrotron data 
collections, attention should be paid to: 
I. The 500-550 cm-1 region, possibly informative about S-S 
rupture. 
II. Two fading-out bands, at 601 and 1385 cm-1, and two 
arising signals, at 665 and 724 cm-1, concerning Met. 
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III. The Fermi dyad bands at 1275 and 1385 cm-1 and the 1410 
cm-1 growing feature, diagnostic for Asp and Glu and 
C-terminal decarboxylation events. 
It is also possible to provide quantitative information on the dose 
needed to produce the observed effects, that is pointing out the 
residue-specific susceptibility to X-ray radiation. As widely 
expected, disulphide bridges are the foremost victim (at about 2 
MGy). The Glu decarboxylation comes next at about 5 MGy closely 
followed by Asp at roughly 7 MGy. The rupture of C-S bonds in 
Met side chains comes at approximately at 13 MGy at last.159,160,193 
These Raman-assisted ultrahigh resolution data could be useful for 
future studies and for a better understanding of how to optimize 
the dose lifetime of macromolecular crystals so that solid guidance 
can be provided to crystallographers. They also demonstrate the 
capabilities of ultrahigh-resolution crystallography teamed with 
Raman microspectroscopy to reveal important details of the 
radiation damage mechanisms, such as the formation of methyl 
radicals and C-terminal region decarboxylation. Indeed, the 
relevant Raman assignment of free CO2 and free CH3 radicals 
represent a few and far between case of crystallography-assisted 
Raman spectroscopy. Definitively, this Raman-assisted 
crystallography protocol can provide a standard 
microspectroscopic procedure for evaluating the X-ray induced 
photodamage in protein crystals, by performing Raman spectrum 
prior and after X-ray exposure particularly during synchrotron 
crystallographic studies.  
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4 
All that glitters 
ain’t gold 
 
 
 
 
 
his section confutes previously reported structural 
crystallographic evidences concerning the co-crystallization of 
gold nanoparticles within protein crystals. A first unsuccessful 
Raman investigation prompted a deeper reanalysis structural data 
deposited in the Protein Data Bank and crystallographic evidences 
for a misinterpretation are reported.  
  
T 
“ 
“ 
All that glisters is not gold- 
Often have you heard that told. 
Many a man his life hath sold 
But my outside to behold. 
Gilded tombs do worms enfold. 
Had you been as wise as bold, 
Young in limbs, in judgment old, 
Your answer had not been inscrolled 
Fare you well. Your suit is cold- 
Cold, indeed, and labor lost. 
 
- The Merchant of Venice- 
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 Introduction 
The high ordered structure of protein single crystals has drawn 
increasing attention in the study of protein-based templates for the 
fine tuning of nanomaterials. Most of the early efforts have been, 
and continue to be, spent for the study of in-solution protein system 
that modulate growth and shape, thus the properties, of 
nanomaterials, particularly nanoparticles.228,229 As previously 
mentioned (see section 1.6 - page 12), gold nanoparticles (AuNPs) 
are surely the most studied and probably the utmost appealing 
nanoscale system. The crystalline arrangement of proteins grants 
sufficiently broad intra-crystal channels to settle nanoparticles and 
substantially slows down their very fast formation kinetics allowing 
for a finer control of AuNPs in size. 
These captivating hybrid systems are attracting increasing interest 
in terms of hybrid nanocatalysts, meant as systems taking 
advantage from catalytic properties either from the crystalline 
enzyme and its nanoparticle counterpart. 
Early works had been conducted mostly by using cross-linked 
proteins but crosslinking spoils the protein tertiary structure likely 
hampering or at least modifying its catalytic behaviour.230 
A deeper comprehension of these systems goes through a better 
understanding of the underlying structural bases. Wei and 
co-authors121 firstly provided a most interesting insight into the 
co-crystallization process between native lysozyme single crystals 
and in-situ grown gold nanoparticles, by using the Au(I) precursor 
ClAuS(CH2CH2OH)2. This method sensibly slows down the growth 
of nanoparticles giving the authors a unique chance to characterise 
the progression of the reaction in a reasonable time scale, study the 
distribution of gold nanoparticles within the crystal by using 
transmission electron microscopy (TEM) and electron tomography 
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(ET). To this point, authors had been able to follow the growth of 
AuNPs within the crystal by following the colour shift of this latter 
from colourless to red, a transition due to the surface plasmon 
resonance (SPR) band of AuNPs.98 TEM and ET strongly supported 
this record providing further details concerning the 
time-dependent AuNPs growth kinetic within the crystal. 
Remarkably, the AuNPs-holding lysozyme crystals did not lose 
their X-ray diffracting power confirming that no major 
rearrangements of the protein structure had occurred, by contrast 
with the previous reports from cross-linked protein crystals. 
Authors indeed adopted X-ray crystallography to further shed light 
on the mechanism underlying the AuNPs formation within the 
crystal from the Au(I) precursor and on the structural aspects of the 
possible interactions between AuNPs and the three-dimensional 
crystalline protein. 
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 Results 
Basing on their X-ray data and successive growth stages (PDB 
accession codes 3P4Z, 3P64, 3P65, 3P66, 3P68), the authors 
advanced a structural-based interpretation for the AuNPs 
formation within the crystal. 
In the attempt to reproduce the procedure proposed by Wei et al.,121 
we have been able to obtain very well diffracting crystal of lysozyme 
in the presence of the ClAuS(CH2CH2OH)2 precursor.  
Anyhow, the analysis of the X-ray data collected from these crystals 
gave no any evidence for the presence of Au atoms within the 
structures.  
This finding prompted us to consider and analyse the experimental 
data and refined models deposited by Wei et al. in the Protein Data 
Bank (codes 3P4Z, 3P64, 3P65, 3P66, 3P68). These structures 
account for nine different gold atoms (four isolated gold atoms and 
a 5-atom cluster). Three out of these five structures show a single 
gold ion bound to His15 and to a monoatomic ligand (Figure 23), 
which Wei et al. reasonably modelled as a chloride ion, considering 
that lysozyme crystals were grown in high NaCl concentrations. 
Finally, five more gold ions are clustered together in the last two 
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deposited crystal structures. For eight out of the nine gold atoms 
found in the structures deposited by Wei et al., it has been possible 
to demonstrate that the authors’ interpretation inaccuracy.  
Surveying our previous and PDB deposited data either, almost all 
gold atoms have been placed by Wei et al. where Cl- or Na+ ions are 
usually found in isomorphous crystals of lysozyme grown using 
condition similar to those adopted in the case: NaCl as a precipitant 
and sodium acetate as buffer solution.
Figure 23 - 2Fo-Fc electron density maps (0.5 e-/Å3) of the Au+ binding site close to His15 
calculated by using data deposited in PDB by Wei et al. Au+ ion is coloured in yellow, whereas 
the Cl- ion is reported in green. The side chain of His15 is also shown. 
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Figure 24 - Electron density difference maps (0.4 e-/Å3) of the “gold atom binding site” close to Tyr23. Negative peaks are coloured in red, whereas positive peaks are in 
green. Maps in the upper row are calculated by using the coordinates deposited in PDB, whereas those reported in the lower row are obtained using coordinates that 
include the substitution of the gold ion with a chloride ion. In addition, Au ions are widely known to form their most stable complexes with “soft” donor atoms such as 
P, S or N; by contrast, in these crystal structures the Au ions have been invariably placed in atypical coordination, e.g. close to Tyr23, Ser24 or Thr43. 
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The analysis of electron density maps has unveiled large negative 
peaks at the position of Au atoms (Figures 23-27), representative 
for an over-interpretation of the local electron density. 
By performing independent refinements using structure factor 
deposited by Wei et al., these negative peaks had disappeared once 
gold atoms had been replaced by Cl–, Na+ ions or even water 
molecules. 
The simple replacements had prompted significant reduction of 
both R-factor and R-free (that is, a better agreement between 
structural models and experimental crystallographic data) in all the 
modified five structures (Table 3). 
Definitively, three out of five crystal structures solved by Wei et al. 
are much more likely to be wild-type lysozyme models, with only 
one Au+ ion bound to His15, rather than crystallographic structures 
for the protein-nanoparticles adduct. The last two crystal structures 
are gold-free. 
  
Figure 25 - Electron density difference maps (0.4 e-/Å3) of the “gold atom binding site”, close to 
Thr43. This site has been found exclusively in the structure deposited in the PDB with code 3P66. 
Negative peaks are coloured in red, whereas positive peaks are in green. Maps in the left panel are 
calculated by using the coordinates deposited in PDB, whereas those in the right one are obtained 
using coordinates that include the substitution of the gold ion with a water molecule.
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Figure 26 - Electron density difference maps (0.4 e-/Å3) of the “gold atom binding site” close to Ser24. This site has not been observed in the structure deposited in the PDB 
with code 3P4Z. Negative peaks are coloured in red, whereas positive peaks are in green. Maps in the upper row are calculated by using the coordinates deposited in PDB, 
whereas those reported in the lower row are obtained using coordinates that include the substitution of the gold ion with a chloride ion.
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The aggregate of these findings weakens, but do not invalidate the 
hypothesis suggested by Wei et al.121 of a protein-mediated metal 
ion transfer preceding the nanoparticle formation, a result that has 
recently been supported by Baksi et al.231 However, the structural 
analysis proposed by Wei et al.121 cannot stand to unveil 
protein-gold nanoparticle interactions because no gold atom is 
unambiguously found in the lysozyme structures reported, apart 
from one ion bound to His15 in the first three structures. This 
means that structural data on biomolecule-directed gold clusters is 
still lacking and the molecular bases of protein-gold nanoparticle 
recognition requires further investigation. 
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Figure 27 - Electron density difference maps (0.4 e-/Å3) for the proposed “gold cluster”. Negative peaks are coloured in red, whereas positive peaks are in green. Maps in the 
upper row are calculated by using the coordinates deposited in PDB, whereas those reported in the lower row are obtained using coordinates that include the substitutions 
of the gold ions with a water molecule, one sodium ion and three chloride ions.  
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Table 3 - R-factor and R-free values before and after substitution of proposed gold atoms, except 
the Au+ close to His15. 
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5 
Zinc-binding 
hCA II inhibitor 
  
 74 
 introduction 
arbonic anhydrases (CAs) are ubiquitous metallo-enzymes 
that catalyse the reversible CO2 hydration reaction.232,233 They 
are widespread in all the kingdoms of life and encoded by six 
evolutionarily unrelated gene families, namely α-, β-, γ-, δ-, ζ- and 
η-CAs.232,234 Human (h)CAs belong to the α-class and exist in 15 
isoforms differing each other by molecular features, oligomeric 
arrangement, cellular localization, tissue distribution, and kinetic 
properties.232 Bearing in mind the critical role of the reaction 
catalysed by CAs, these enzymes are involved in a variety of 
physiological/pathological processes, consequently becoming 
high-value targets for pharmaceutical research, and a number of 
studies have been reported on CA inhibitors (CAIs) in recent 
years.232,235-238 In particular, the elucidation of their mechanism of 
action went through crystallographic analyses of several 
enzyme-inhibitor adducts allowing to determine the molecular 
bases of enzyme-inhibitor interactions.232 The most effective CAIs 
are sulphonamide/sulfamate-based molecules interacting with the 
enzyme active site by coordinating the zinc ion and displacing a 
water molecule/hydroxide ion;232 however, these molecules are 
generally poorly selective towards different CA isoforms. To this 
end, new zinc binding groups are continuously tested to advance in 
the identification of isoform-selective CAIs.239,240 
Herein, RAC has been deployed to support and disambiguate 
structural aspects for the inhibition mechanism of a newly 
synthesised CAI, hydroxylamine-O-sulphonamide 1 (Figure 28), a 
molecule containing two zinc binding groups, namely the 
sulphonamide and hydroxylamine. This molecule has been 
C 
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synthesised by co-authors at the CNR Institute of Biostructures and 
Biomages – Naples, who also performed the inhibition profile study 
towards the different hCAs isoforms. 
The opening hypothesis was that two functional groups could give 
an ambidentate character to this derivative. Previous data show 
compound 1 to possesses interesting inhibition profiles and 
binding modes towards hCA isoforms, as it can bind the Zn ion of 
CA active site with both Zn-binding groups, suggesting that the 
derivatisation of the sulphonamide nitrogen and of the 
hydroxylamine moiety can be used to obtain new classes of 
inhibitors. 
  
Figure 28 - Chemical structures of compounds 1–5. 
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 Experimental and Results 
The inhibition profile of 1 against all catalytically active hCA 
isoforms was investigated by co-authors showing that this molecule 
has a rather variable behaviour against different isoforms. Indeed, 
1 behaves as a potent inhibitor towards hCA II and hCA VA, (KIs 
of 50.9-55.5 nM), as a medium-strength CAI towards several other 
isoforms (e.g. IV, IX and XII - KIs of 133.6–161.9 nM), whereas 
hCA III, VII and XIII are inhibited with constants in the 326–608 
nM range. Three isoforms (hCA I, VI and XIV) are not inhibited 
significantly by compound 1. This unique profile is of interest for 
developing new inhibitors. 
5.2.1 X-ray crystallography 
To elucidate the binding mode of 1 to the CA active site, the 
structure of the adduct that this molecule forms with the best 
characterized hCA isoform, namely hCA II, has been solved 
(accession code 4YVY). The hCA II/1 crystals have been obtained 
and the three-dimensional structure has been analysed through 
difference Fourier techniques by co-authors. 
Inspection of the initially calculated electron density maps in the 
active site cavity has showed clear evidence for the binding of the 
inhibitor to the catalytic zinc ion. Anyhow, these maps have not 
allowed for unambiguously discriminating the inhibitor binding 
mode though being very well defined. Indeed, two different models 
fit in and compatible with the electron density maps: the first one - 
hereafter indicated as binding mode A - with the catalytic zinc ion 
coordinated by the sulphonamide nitrogen and the second one – 
binding mode B from now on - where the coordination was due to 
the hydroxylamine moiety in a side-on (η2) fashion (Figure 29).241 
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Figure 29 - Active site region in the hCA II/1 adduct, showing the sA-weighted |Fo–Fc| OMIT 
map (contoured at 3.0σ). The two possible coordination modes of inhibitor 1 are reported. 
The zinc ion coordination is drawn in black and red for binding modes A and B, respectively. 
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5.2.2 Raman microspectroscopy 
To get preliminary information on the Zn2+ coordination in the 
hCA II/1 complex, Raman microspectroscopy has therefore been 
performed on the hCA II single crystals with or without the 
inhibitor either (Figure 30). 
All of the Raman data collections have been carried out using a 
Jasco NRS-3100 microscope and a 514 nm line from a Ar+ laser as 
light source. A 20x objective granted a focused spot size of 
approximately 2 μm while laser line rejection has been guaranteed 
by a holographic notch filter. The Raman backscattering has been 
collected at 180° by using a 0.1 mm slit and a 1200 grooves/mm 
grating, corresponding to an average spectral resolution of 7 cm-1. 
The minimum exposure time of collected spectra has been 60 
seconds by using a Peltier-cooled 1024x128 pixel Andor CCD 
photon detector. Wavelength calibration has been performed by 
using cyclohexane as a standard. Raman microspectroscopy 
measurements on hCA II crystals have been conducted keeping 
Figure 30 - Raman spectra of the hCA II native crystals, inhibitor 1 and hCA II/1 complex 
crystals. Mother liquor (ML) is also reported to detect signals from it (*). 
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crystals into a drop of mother liquor, using a common 24-well 
hanging drop crystallization plate. 
Several Raman signals from hCA II have been clearly observed in 
the crystal (e.g. amide I band at around 1666 cm-1, and Phe ring 
band at around 1007 cm-1) besides strong signals from mother 
liquor. Upon inhibitor 1 addition, these signals are almost 
unaltered whereas a novel significant Raman band appeared at 
around 322 cm-1. This band is absent in the spectra collected from 
the native crystals, the inhibitor powder and the mother liquor 
(Figure 30) and could confidently be assigned to vibrational modes 
related to the binding of the inhibitor to the enzyme, in particular, 
to stretching modes between Zn2+ and O and/or N atoms. 
Unluckily, no aid came from literature for unambiguous 
assignment. A crystallography-assisted Raman analysis has been 
therefore adopted and further Raman experiments have been 
performed on hCA II native crystals soaked with two different 
inhibitors, namely compounds 2 and 3 in (Figure 28), whose Zn2+ 
ion coordination had been defined clearly and unambiguously by 
previous crystallographic investigations.242,243 
Explicitly, inhibitor 2 coordinates the catalytic zinc ion through O 
atoms,242 whereas compound 3, the widely known CA inhibitor 
acetazolamide (AZM), binds via the sulphonamide nitrogen atom, 
the very same way described above for the binding mode A.243 
Raman spectra of the hCA II/2 adduct did not show any band at 
around 322 cm-1 whereas those on the hCA II/3 complex exhibited 
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a clear Raman signal at around 324 cm-1, very close to the one seen 
in the hCA II/1 adduct (Figure 31). 
Thus, these crystallography-assisted Raman data suggested that in 
analogy with the hCA II/3 complex, at least partial Zn2+ ion 
coordination occurs via the sulphonamide nitrogen atom in the 
adduct under investigation, even though it has not been possible to 
utterly rule out alternative coordinations. 
Regrettably, no Raman data were available for side-on Zn2+-ligand 
coordination. To this end, some DFT244,245 and Raman data gathered 
form other metals with nitrosyl or peroxo-species have been taken 
into account.245,246 DFT calculations foreseen significant structural 
differences between end-on and side-on coordination,245 while 
Raman data pointed out a noteworthy switch in the low frequency 
mode between end-on and side-on-metal–ligand coordination.247 
Raman spectra did not show any additional signal beyond the one 
at 322 cm-1 corresponding to the AZM-like coordination, 
prompting the hypothesis that the alternative side-on coordination 
Figure 31 - Raman spectra comparison among wild type hCA II and three complexes with 
the corresponding compounds. 
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of the hydroxylamine moiety was not detectable by Raman 
microspectroscopy due to low Raman cross-section. At this point, 
the side-on frequency mode have been assumed not to fall below 
the end-on AZM-like Raman band (around 322 cm-1), thus 
allowing for the quantitative analysis reported below. Indeed, 
considering the hCA II/3 adduct binding to exclusively occur via 
N-coordination,243 our Raman analysis also permits a putative 
quantitative evaluation for the AZM-like binding in the hCA II/1 
complex. More in detail, by assuming the Raman cross-section of 
the Zn2+–N band at around 322 cm-1 to be the same for either the 
hCA II/1 and hCA II/3 complexes, and using the signal of the Phe 
band at 1007 cm-1 as an internal reference for spectra 
normalization, a fraction of 0.4±0.1 has been evaluated to be bound 
as AZM-like for compound 1. 
Altogether, Raman data hence suggest that 40% of the coordination 
of the catalytic Zn2+ ion in the hCA II/1 complex occurs through 
the sulphonamide nitrogen (binding conformation A) and for the 
remaining 60% through binding coordination not identifiable from 
Raman experiments. 
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 Discussion 
Basing on these data, the two initially hypothesised alternative 
binding conformations have been modelled in the electron density 
maps (Figure 29). The atomic occupancy factors Q have thus been 
refined by fixing their respective B-factor to values comparable to 
those of the solvent within the active site. Interestingly and in good 
agreement with Raman spectroscopy data, the occupancy factors Q 
have been pinpointed at 0.33 and 0.34 for binding conformation A 
and B respectively. Since the aggregate of inhibitor binding 
conformations Q adds up to 0.67 and residual electron density yet 
was appreciable in the surrounding of the zinc ion, an alternative 
water molecule coordinated to the zinc ion at Q=0.33 has been 
added to fill-up the gap. The protein–inhibitor interactions for both 
binding modes A and B are shown in Figure 32. 
Interestingly, though a number of studies suggest that 
sulphonamides generally coordinate to the catalytic zinc ion 
through a deprotonated nitrogen atom, the pKa values calculated 
by co-authors for the hydroxylamine and sulphonamide moieties 
Figure 32 - Zn2+ coordination geometry in the hCA II/1 adduct for binding conformation A 
(A) and B (B). Hydrogen bonds and residues forming van der Waals interactions are also 
reported. 
 83 
of compound 1 using the Marvin software248 gave different 
indication. At the pH condition adopted for crystallization 
experiments, the inhibitor exists as a non-deprotonated form in 
both binding forms. 
It is worth noting that compound 4,249 a strictly related isomer of 
compound 1 (Figure 28), adopted only one conformation within 
the hCA II active site, coordinating the zinc ion through the 
sulphonamide nitrogen atom, as observed in conformation A of the 
hCA II/1 adduct. 
 
Figure 33 - (A) Zn2+ coordination geometry in the hCA II/4 adduct (PDB code 2O4Z). (B) 
Structural superposition of 1 in conformation A and 4 when bound to the hCA II active site. The 
active site residues of hCA II/1 and hCA II/4 adducts are coloured in pink and green, respectively. 
Inhibitor polar interactions are drawn in black for hCA II/1 and red for hCA II/4. 
 
The inhibitor binding mode observed in hCA II/1 has been 
compared to that of a classical benzene-sulphonamide, namely 
compound 5250 (Figure 33A and B). Interestingly, while the 
sulphonamide moiety of 1 in the binding conformation B is 
perfectly superimposable to the sulphonamide group of 5, the same 
moiety in binding conformation A assumes a position completely 
different from that of benzene-sulphonamide 5. 
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On the basis of these data, it is possible to hypothesise that 
derivatization of compound 1 on the hydroxylamine moiety, thus 
forcing the binding conformation A, could allow the inhibitor to 
interact with regions of the active site not yet explored using 
classical benzene-sulphonamides. 
Altogether, these results strongly suggest that the 
hydroxylamine-O-sulphonamide inhibitor represents an 
interesting lead compound alternative to the classical 
sulphonamides for the development of more selective CAIs. 
The last few years saw the discovery of an entire new range of CAIs 
possessing a variety of non-classical inhibition mechanisms.232 
Indeed, for more than 60 years, since the report of sulphonamides 
as CAIs, the drug design landscape has been dominated by these 
compounds and their isosteres, the sulphamates and sulphamides. 
They possess a rather simple inhibition mechanism, as they bind in 
deprotonated form to the metal ion from the active site, as the 
fourth ligand.232 However, starting from 2008 completely new 
chemotypes were reported as CAIs: the coumarins,251 the 
polyamines,252 dithiocarbamates,253 xanthates,254 hydroxamates,242 
sulfocoumarins,255 carboxylates, etc.240,256 Many of them possess an 
inhibition mechanism strikingly different compared to the classical 
one. Some of these inhibitors anchor to the zinc-coordinated water 
molecule (polyamines, sulpho-coumarins, and some 
carboxylates),252,255,256 others bind towards the exit of the active site 
cavity in the activator-binding site (coumarins and their 
derivatives),251,257,258  whereas some carboxylates are even observed to 
be bound out-of-the active site.240 The compound investigated here, 
hydroxylamine-O-sulphonamide 1, although possessing a simple 
chemical structure, is unique due to its versatility in inhibiting these 
enzymes, being the first example in which two alternative 
coordinations to the metal ion were evidenced. As aforementioned, 
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compound 1 is partially coordinated classically, as all 
sulphonamides/sulphamates, binding the Zn2+ ion through the 
sulphonamide nitrogen and partially through the hydroxylamine 
moiety in a side-on (η2) fashion, which is a common inhibition 
pattern for this family of enzymes. The aggregate of these facets can 
definitely be exploited for drug design purposes as the chemical 
simplicity of compound 1 is amenable to elaboration through 
medicinal chemistry purposes. 
Besides chemical implications and medicinal exploits, we herein 
shown an original crystallography-assisted Raman spectroscopy 
approach for investigating the binding mechanism of compound 1 
to hCA II. This approach allowed to identify and disambiguate the 
hydroxylamine-O-sulphonamide binding modes to Zn2+ and 
proved to have a more general utility in the investigation of metal 
ion coordination when standalone X-ray crystallography or Raman 
microspectroscopy cannot provide unarguable response. 
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6 
Iridium CO-releasing 
molecule 
 combination of mass spectrometry, Raman 
microspectroscopy, circular dichroism and X-ray 
crystallography has been used to obtain detailed information on the 
reaction of an iridium-based CO-releasing molecule (Ir-CORM), 
Cs2IrCl5CO, with a model protein, bovine pancreatic ribonuclease. 
The results show that Ir-compound fragments bind to the N-terminal 
amine and close to histidine and methionine side chains, and the CO 
ligand is retained for a long time. The data provide helpful 
information for identifying protein targets for Ir-CORMs and for 
studying the mechanism that allows them to exhibit their interesting 
biological properties. 
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 Introduction 
The properties of some metal-containing compounds in the 
treatment of selected human diseases have been known since long 
but, after the cisplatin breakthrough and its derivatives in the 
treatment of tumours, the interest of the scientific community 
towards the synthesis and characterization of potential drugs based 
on metal compounds has sensibly grown and numerous complexes 
of diverse metals, including iridium, have been tested as 
pharmacological agents. Tough the mechanisms of action of these 
compounds have not yet been entirely deciphered, it is as clear as 
day that DNA is not the sole primary target, as for Pt based 
drugs.4,91,259 
The study of the interaction of metal-based drugs with proteins is 
thus of crucial importance to unveil the mechanism of action of 
these important pharmacological agents and several reviews have 
been published in this field.260-262 
Among the metal-based drugs, CO-releasing molecules (CORMs 
from now on)46,263-266 based on complexes of Mn, Fe, Co, Ru and 
Ir,41,55,267,268 are drawing increasing attention from medicinal 
(inorganic) chemists because of their promising bactericidal,41,47 
anti-inflammatory,269,270 anti-apoptotic,270 anti-microbial271 and 
anti-proliferative properties.272 
To understand the biological properties of CORMs in detail, it is 
important to characterise their interactions with possible biological 
targets, to define the binding sites of the metal, and to determine 
which among the original ligands are still present upon formation 
of the adduct. The binding of CORMs to proteins can play an 
important role in their activation, transport, and in-vivo 
excretion.273 A few structural studies of protein-CORM adducts 
have been performed, but the knowledge of how CORMs recognise 
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proteins and of the mechanism which allows CORMs to release CO 
in the presence of a protein is still rather limited. Crystallographic 
studies on the first protein-CORM adduct, carried out using hen 
egg white lysozyme (HEWL) as a model protein, have 
demonstrated that the Ru complex CORM-3 can bind to surface 
histidine and aspartic residues.54 Subsequently, it has been shown 
that ruthenium-based CORMs can bind HEWL at diverse sites, i.e. 
close to His15, Asp18, Asp101 and Asp119.53,274 
Recently, a structural characterisation of the adducts that are 
formed when HEWL reacts with the Ir-based CORM Cs2IrCl5CO 
has been performed.43,55 It has been found that the adducts can be 
formed via covalent or non-covalent interactions either. Six 
different binding sites have been identified (His15 (site 1); Ser24, 
Asn27, and Val120 (site 2); Asn65 and Pro79 (site 3); Asp18 (site 
4); Asn59, Trp62, Trp63, and Ala107 (site 5); and Asn46 and Thr47 
(site 6)), although His15 seems to be the primary anchoring site for 
the Ir derivatives. Loss of CO in the crystal state has been also 
observed both via X-ray crystallography and Raman 
microspectroscopy.55 
This section addresses for the investigation of the reactivity of 
Cs2IrCl5CO with the model protein bovine pancreatic ribonuclease 
(RNase A) by using mass spectrometry (MS), X-ray crystallography 
and Raman microspectroscopy. The stability of the adduct formed 
upon reaction of the protein with the potential metallo-drug has 
been also evaluated using circular dichroism. 
  
 90 
 Experimental section 
6.2.1 Crystallization and data collection 
The crystals of the adduct formed in the reaction between RNase A 
and IrCl5CO2− were obtained using a soaking procedure. In 
particular, crystals of RNase A have been grown over two weeks 
using a hanging-drop vapour-diffusion method with a reservoir 
solution containing 22% PEG 4K and 10 mM sodium citrate at pH 
5.1. They have been soaked with a saturated solution of Cs2IrCl5CO. 
After four days (crystal 1) and two months (crystal 2) of soaking, 
these crystals have been fished out with a nylon loop, flash-cooled 
without cryoprotectants at 100 K using nitrogen gas and 
dehydrated under air,275 as performed in other works.276,277 
Data have been collected at 1.85 and 2.29 Å resolution for crystals 
1 and 2, respectively, at the CNR Institute of Biostructure and 
Bioimages, Naples - Italy, using a Saturn944 CCD detector along 
with CuKα X-ray radiation from a Rigaku Micromax 007 HF 
generator, and processed using HKL2000. Details of the data 
collection statistics are reported in Table 4. 
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Table 4 - Data collection and refinement statistics. Values within brackets refer to last resolution 
shell. 
 
6.2.2 Structure solution and refinement 
The structures of the two RNase A-IrCl5CO2- adducts have been 
solved with PhaserMR, using the A chain of the PDB file 1JVT as a 
starting model.278 As expected,278 these crystals contain two 
molecules in the asymmetric unit (molecule A and molecule B). The 
refinements have been carried out with CCP4 Refmac5279 using 
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NCS restraints while the model building, map inspections and 
model adjustments have been manually performed with Coot 
v0.8.6.280 The structures have been refined up to R-factor/R-free 
values of 0.172/0.226 and 0.224/0.293 for crystal 1 and crystal 2, 
respectively. 
Table 1 reports the refinement statistics. Figures were created using 
the UCSF Chimera Package.281 The refined structural models and 
structure factors were deposited in the Protein Data Bank as entries 
5JMG and 5JML for crystal 1 and crystal 2, respectively. 
 
6.2.3 Raman microspectroscopy 
Raman microscopy spectra for the RNase A crystals and for crystals 
of the RNase A-IrCl5CO2- adduct have been collected by using a 
commercial Jasco N3100 microscope apparatus, Raman spectra of 
the Cs2IrCl5CO powder have been collected as references as well. A 
514 nm excitation wavelength and a power at the sample of 3 mW 
have been used. The spectra resolution 7 cm-1. 
 
6.2.4 Mass spectrometry 
MS analysis has been performed by co-authors using an LCQ 
DECA XP Ion Trap mass spectrometer (ThermoElectron) 
equipped with an OPTON ESI source (operating at a 4.2 kV needle 
voltage and 320 °C). The mass spectra have been recorded 
continuously over the mass range 400-2000 Da in positive mode. 
Multi-charge spectra have been deconvoluted using a BioMass 
program included in the Bioworks 3.1 package provided by the 
manufacturer. 
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6.2.5 Circular dichroism 
CD spectra of RNase A and of the adduct formed between the 
protein and IrCl5CO2- after 24h of incubation with 1:1 and 1:10 
protein to metal ratios were recorded at 10 °C using a Jasco J-710 
spectropolarimeter equipped with a Peltier-thermostated cell 
holder (Model PTC-348WI - Jasco). 
The mean residue molar ellipticity, [θ] in deg cm2 dmol-1, has been 
calculated using the equation: 
 ! = ! #$%×'()/(10./) 
 
where [θ]obs is the ellipticity measured in degrees, MRW is the mean 
residue molecular weight, c is the protein concentration in g mL-1 
and l is the optical path length of the cell in centimetres. 
Far-UV measurements (190-250 nm) have been carried out using a 
0.1 cm path length cell and a protein concentration of 0.1 mg mL-1 
in a 10 mM Tris-HCl buffer, pH 7.4. Prior the measurements, the 
instrument has been calibrated with an aqueous solution of 
d-10-(+)-camphorsulphonic acid at 290 nm. Thermal unfolding 
curves for the protein and the adduct have been recorded using the 
temperature mode at 222 nm with the same experimental 
conditions, meaning protein concentration of 0.1 mg mL-1 in a 
10 mM Tris-HCl buffer at pH 7.4. 
 
  
 94 
 Results and discussion 
6.3.1 Mass spectrometry 
In order to study the reactivity of Cs2IrCl5CO with proteins, 
RNase A has been incubated in the presence of the Ir compound for 
24h with a 1:10 protein to metal ratio, and the resulting products 
have been analysed using electrospray ionization mass 
spectrometry (ESI-MS). The results of this analysis are reported in 
Figure 34. The spectra of RNase A incubated in the presence of 
IrCl5CO2- reveal that a number of different Ir compound fragments 
can bind to the protein. In particular, when compared to RNase A 
spectra, new peaks have been detected in the ESI-MS spectra of the 
adduct, that have been assigned to a complex formed by RNase A 
with fragments like -[IrCl4CO]- and -[IrCl3(H2O)CO]. 
Interestingly, more than one Ir fragment could bind to the protein 
at the same time and the observation of these peaks suggests that 
the CO is retained upon protein binding, while a Cl− ligand is 
released. 
Figure 34 - Deconvoluted ESI-MS spectra for RNase A incubated for 24h at room temperature 
with 10-3 mol L-1 Cs2IrCl5CO dissolved in water (complex/protein = 10:1) in 20 mmol L-1 
ammonium acetate buffer, pH 6.8. The symbols indicate the main peaks of several adducts: *: 
RNase A + Na+, ¥: RNase A + 2Na+, #: RNase A + Cs+. 
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6.3.2 Circular dichroism 
In order to verify the effect of the IrCl5CO2- binding on the RNase 
A structural stability, CD spectra have been recorded (Figure 35) 
and the signal intensity at 222 nm monitored for increasing 
temperature values (from 10 °C to 95 °C - Figure 36). The far 
UV-CD spectra of RNase A and of the adducts formed upon 24h of 
incubation of the protein in the presence of the Ir compound at 1:1 
and 1:10 protein to metal molar ratios are indistinguishable 
(Figure 36) at 10 °C in 10 mM Tris-HCl buffer at pH 7.4. They 
contain typical fingerprints of α/β proteins and the inspection of 
unfolding curves clearly indicates that the thermal denaturation of 
RNase A is not affected by the IrCl5CO2- binding (Figure 36). 
These findings demonstrate that the binding of IrCl5CO2- fragments 
to RNase A does not perturb the overall protein conformation or 
structural stability neither. 
Figure 35 - Far-UV CD spectra of RNase A and RNase A-IrCl5CO2- adducts formed with 1:1 and 
1:10 protein to metal molar ratios. Spectra have been collected at 10 °C using a protein 
concentration of 0.1 mg mL-1 in a 10 mM Tris-HCl buffer, pH 7.4. 
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Figure 36 - Thermal denaturation of RNase A and RNase A-IrCl5CO2- adducts formed with 1:1 
and 1:10 protein to metal molar ratios, as obtained from CD spectroscopy at 222 nm. 
Measurements have been carried out in 10 mM Tris-HCl buffer, pH 7.4, using an enzyme 
concentration of 0.1 mg mL-1. Heating rate was 1.0 °C min-1. 
 
6.3.3 Structure of the adducts 
To explore the reactivity of IrCl5CO2- with RNase A on structural 
ground, the structure of the adducts has been determined by X-ray 
crystallography, using two different datasets both collected on 
monoclinic crystals grown under the same conditions and 
containing two RNase A molecules in the asymmetric unit. These 
crystals differ each other in soaking time of the Ir compound. X-ray 
diffraction data for the first crystal have been collected after four 
days of soaking in a saturated solution of Cs2IrCl5CO, whereas data 
for the second crystal have been collected after two months. 
Interestingly, the two structures show a different number of 
Ir-compound binding sites. Indeed, five sites have been identified 
in crystal 1 (N-terminal amine, Met29, His105 and His119 in 
molecule A and His119 in molecule B), whereas eight sites have 
been found in crystal 2 (N-terminal amine, Met29, His12, His105 
and His119 in molecule A, His12, His105 and His119 in molecule 
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B). In both cases, the structure of the protein is not significantly 
affected by the reaction with the CORM: the four disulphide bridges 
are retained and the CA root mean square deviations from a 
ligand-free protein under the same experimental conditions (PDB 
code 1JVT) is in the range 0.19-0.42 Å. 
Figure 37 illustrates the asymmetric unit content for the structures 
of the two RNase A-IrCl5CO2− adducts. 
The final model obtained for the RNase A-IrCl5CO2- adduct in 
crystal 1 (Figure 37A) includes 2238 non-hydrogen atoms and has 
been determined at a 1.85 Å resolution. This structure refines to an 
R-factor of 0.172 (R-free 0.226). The average B-factor for all atoms 
of the structure is 26.4 Å2. A full list of the refinement statistics is 
reported in Table 1. Figure 38 shows the 2Fo-Fc electron density 
maps for the five Ir-compound binding sites identified in this 
structure. The occupancy factors for the Ir atoms are in the range 
0.30-0.60. In molecule A, at the first Ir compound binding site, i.e. 
close to N-terminal amine, the Ir atom is bound to a Cl- and is in 
contact with the side chain of Arg85 from a symmetry-related 
molecule (Figure 38A). This finding indicates that upon hydrolysis, 
Cs2IrCl5CO can act as a cross-linker, bridging different protein 
chains, as already observed for cisplatin and other 
metallodrugs.282,283 At this site, the electron density maps do not 
allow for a complete elucidation of the iridium coordination sphere.  
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Figure 37 - Cartoon diagram of the RNase A structures in the asymmetric unit from crystal 
1 (A) and crystal 2 (B). Ir compounds are represented by ball and stick structures, as are the 
residues involved in the compound recognition (N-terminal Lys, His12, Met29, His105, and 
His119). Molecule A is on the right. 
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Figure 38 - Details of the IrCl5CO2− binding sites in crystal 1 (A–D) and of the additional 
IrCl5CO2− binding sites in crystal 2 (E, F). (A) N-terminal amine (molecule A), (B) His105 
(molecule A), (C) His119 (molecule B), (D) Met29 (molecule A); (E) His105 (molecule B of 
crystal 2); (F) His12 in the active site cleft (molecule A from crystal 2). 2Fo-Fc electron density 
maps are contoured at 1.5σ (blue) and 2.5σ (orange) levels. 
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In molecule A, at the binding site close to the His105 side chain, a 
[IrCl(H2O)3CO]2+ fragment is bound to the protein (Figure 38B). 
The same fragment is bound to the active site residue His119 of 
molecule B (Figures 38C and 39). The product of hydrolysis of this 
fragment, i.e. [Ir(H2O)4CO]3+, is linked to the Met29 side chain of 
molecule A (Figure 38D), with a CO ligand occupying an equatorial 
position with respect to the Met side chain. The observation of this 
binding site is interesting because even though Ir-based 
compounds are known to bind protein sulphur sites,55 the 
interaction between sulphur containing residues and Ir complexes 
has never been described from a structural point of view. Finally, 
the Ir compound fragment bound to His119 of molecule A presents 
a metal coordination shell completed by water molecules 
(Figure 39). 
The structure of the RNase 
A-IrCl5CO2- adduct in crystal 
2 has been refined at a lower 
resolution (2.29 Å). This 
model includes 2027 
non-hydrogen atoms and 
refines to an R-factor of 0.224 
(R-free 0.293). In this 
structure, three additional Ir 
binding sites were identified 
compared to those observed 
in crystal 1 (Figure 38 E, F). The occupancy factors of the Ir atoms 
are in the range 0.30-1.00. A full list of the refinement statistics is 
reported in Table 4. The first two additional binding sites are close 
to His12 in the two molecules, in the active site clefts. In these sites, 
the metal is bound to His12 and Gln11 side chains (Figure 38F) and 
is modelled as an alternative to the Ir compound bound to His119. 
Figure 39 -  Details for the IrCl5CO2- binding site 
close to His119 of molecule A from crystal 1. 2Fo-Fc 
electron density map is contoured at 1.5 σ (blue) 
and 2.5 (orange) level. 
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The other additional binding site has been observed at the side 
chain of His105 of molecule B (Figure 38E). Here, a 
[IrCl2(H2O)2CO]+ fragment is bound to the protein. 
Interestingly, in this structure the fragment bound to His119 of 
molecule B ([Ir(H2O)4CO]3+) is different when compared to the one 
found in crystal 1 ([IrCl(H2O)3CO]3+ - Figure 38C), suggesting that 
ligand exchange processes are possible upon protein binding. 
Additional details of the Ir compound fragments identified in the 
two structures are reported in Table 5. 
 
Table 5 - Additional details of the Ir compound fragments identified in the two structures of 
RNase A–IrCl5CO2− and the interactions that they form with protein residues 
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6.3.4 Raman microspectroscopic studies 
Raman spectra have been collected to obtain unambiguous 
evidence of the presence and persistency (no release) of CO within 
the crystals of the adduct (Figure 40). The Cs2IrCl5CO powder 
shows signals due to Ir-Cl bond stretching in the 300-400 cm-1 
region and a signal at about 2080 cm-1 assigned to the CO ligand, 
also according to previous findings.55 
Looking at the spectra collected over 2 weeks from the IrCl5CO2− 
soaking, it shows that the metallo-drug is able to enter into the 
protein crystals as marked by the appearance of the high-frequency 
band at 2073 cm-1, after just a few minutes from the Ir soaking. This 
spectral feature it due to the CO bound to the metal centre and 
remains stable for two weeks suggesting that the CO ligand is not 
released under the experimental conditions. 
Figure 40 - Raman spectra of the Cs2IrCl5CO powder and RNase A crystal, and of protein 
crystals soaked in a saturated solution of Cs2IrCl5CO as a function of time. The star refers to 
signals from the buffer. Excitation line wavelength is 514 nm with power at the sample of 
3 mW and spectral resolution of 7 cm-1. The CO band persistency indicates that no CO release 
is occurring in the crystals of the adduct. 
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This is conflicting with evidences form previous study on the 
reactivity of the same compound within lysozyme crystals,55 where 
IrCl5CO2- has been shown to be able to release the CO ligand as 
demonstrated by the appearance of new Raman spectral features in 
the 2000-2200 cm-1 region (CO stretching region, see Figure 9 and 
10 in Petruk et al.55). In addition, the band at around 300 cm-1 
related to the Ir-Cl stretching appear sizeably attenuated in the case 
of RNase A, differently from previous Raman records from the 
lysozyme-IrCl5CO2- adduct (crystals grown in 1.2 M NaCl).55 The 
different behaviour clearly relates to the NaCl-free condition for the 
study the formation of the RNase A-IrCl5CO2- adduct, which likely 
undergoes to hydrolysis reaction. By contrast, the much slower 
Cl-/H2O exchange observed for the HEWL-IrCl5CO2- adduct relies 
and the high concentration of Cl- ions in the solution used to obtain 
the HEWL crystals. 
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 Conclusions 
Interactions between CO-releasing compounds and biological 
macromolecules have received increasing attention over the past 
decade. Here I reported a combination of spectrometric 
spectroscopic crystallographic investigations for unveiling the 
molecular bases of protein/Ir-based CORM recognition. 
Basing on findings in this work, the following concluding marks 
can be drawn: 
a) IrCl5CO2- tightly binds to RNase A at its N-terminal amine 
and at the His12, His105, His119 and Met29 side chains. 
Histidine residues have been earlier found to bind Ir-based 
metallo-drugs in other structures,55 but details for the 
Met-Ir interactions and for the N-terminus involvement 
have never been shown before though sulphur-containing 
ligands are strong binding sites for heavy transition metal 
ions. For example, it has been shown that cisplatin and 
carboplatin bind to the sulphur atom of Met29 of 
RNase A,209,282,284 to the cytochrome c Met65 sulphur atom,285 
and to the Met side chains of Na+/K+ ATPase286 and human 
serum albumin.287 
b) IrCl4CO2- and the products of its hydrolysis bind to the 
protein. 
c) the formation of the adduct does not significantly affect the 
overall enzyme structure. 
d) the RNase A-IrCl5CO2- adduct is stable under the 
investigated experimental conditions. 
e) the adduct formed in the reaction between RNase A and the 
IrCl5CO2- compound retains a significant amount of CO for 
at least two months, further confirming the idea that the 
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formation of complexes between proteins and CORMs can 
be used for modulating the kinetics of CO release.55,288,289  
f) the adduct has the same thermal stability as the ligand-free 
protein. 
These findings gain a larger relevance putting this work in the 
general framework of iridium compound-protein interactions. 
Iridium complexes have received considerable attention in very 
diverse fields such as catalysis,290 optoelectronics and inorganic 
photochemistry,290,291 medicinal inorganic chemistry and biology.292 
Furthermore, they work as chemo-sensors for live cell imaging and 
in-vivo tumour imaging,37,293 as well as protein-protein interaction 
inhibitors. Negatively charged Ir complexes alike (IrCl6)3- have been 
proved to bind basic protein regions i.e. His residues through 
nucleophilic substitution of a metal ligand, usually a chloride, by 
the imidazole.55 
Taking advantage of these properties, the cyclometalated Ir(III) 
solvato complex [Ir(ppy)2(solv)2]+ has been used as a selective 
luminescent switch-on probe for His-rich proteins.294 By contrast, 
positively charged complexes like (Ir(NH3)6)3+ are likely to bind 
acidic regions in the protein. 
This section shown Ir(III) complexes to be also able to bind Met 
side chains and N-terminal amines helping to understand and 
predict the biomolecule-Ir compound interactions, as well as 
support future drug design. 
At last, it is worth noting that the two Raman studies for lysozyme 
and RNase A with IrCl5CO2− suggest a possible correlation between 
the CO-releasing ability of the Ir compound and its Cl-/H2O 
content, at least in the time scale of the Raman analysis (2 weeks): 
the higher the content of Cl- in the coordination sphere, the faster 
the CO release within the crystal though further studies are needed 
to validate this hypothesis. 
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7 
Ruthenium prodrug 
release from protein 
he Ru(III) drug AziRu efficiently binds proteins but its release 
mechanism remains disputed. Herein, we perform a Raman-
assisted crystallographic study of AziRu binding to lysozyme and its 
chemical reduction to test the Ru release conditions, by using three 
different reducing agents. Different outcomes have been achieved 
spanning from the complete crystal dissolution, through a complete 
Ru release up to the Ru reduction without release. The aggregate of 
our spectroscopic and crystallographic findings highlights the 
reduction to be necessary though no self-sufficient in the prodrug 
activation/release mechanism. At last, these findings support the 
possible environ-specific activation of the prodrug within cancer 
environments because of the different chemical conditions as 
compared to healthy tissues. 
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 introduction 
Last decades saw a significant increase of the ruthenium-based 
designs as anti-cancer agents.16 Notwithstanding that the details of 
their mechanisms of actions remain unclear, ruthenium-based 
drugs are known to owe much of their success in the current 
anticancer panorama to the ease they access different oxidation 
states under physiological conditions.16,81 Ru(III) is the prevailing 
and most stable form though marginally anticancer active and 
largely bound to blood-plasma proteins once administered, 
essentially acting as a prodrug.4,58,64 Indeed, Its anti-tumour 
potential has been proven to rely on the reduction to Ru(II),61,82,83 
widely recognised as the utmost anticancer-active ruthenium 
form.4,58,64 Ru(II), alike Ru(IV), can be promptly accessed in the 
presence of ordinary biological redox agents, particularly abundant 
within cancer environs opening perspective for possible selective 
drug activation.4,25,64,82-85 In addition, the structures, speciation in 
biological environs, exact molecular targets and action mechanisms 
have not yet been elucidated.16 
A number of complexes have been proposed and, albeit none of 
them has achieved to reach actual clinical usage as yet, two 
acclaimed complexes introduced roughly at the same time, namely 
NAMI-A, and KP1019 have both reached phase II in clinical trials 
showing remarkable performance.11,16,58,59,62 
The subject of this study is the recently proposed AziRu complex, 
whose structure differs from NAMI-A for a pyridine ring in place 
of imidazole (Figure 41).295 It has proven to possess a higher 
cytotoxicity and anti-proliferative capacity than its 
imidazole-substituted counterpart.295,296 Tests in conjugation with 
nanocarriers have proven a sizeable increase in the cell delivery rate 
as well,296 whilst the combination of X-ray crystallography and 
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Raman microspectroscopy granted evidences from a structural 
point of view on interaction with the two model proteins, RNase A 
and Lysozyme, as well as shedding light on the ligand exchange 
process.18,297 
Electron-paramagnetic resonance has given clues for the plasma 
proteins-mediated transport of aquated Ru(III) species, also 
indicating the binding to occur through Cys and His side chains.298  
Previous crystallographic studies supported by Raman findings on 
the binding of AziRu with lysozyme, ribonuclease, and 
cytochrome c, report the binding to occur via His, Asp and Arg side 
chains.16-18,297 
In aqueous solution, the AziRu undergoes to the aquation process 
and the early solution appears yellowish (Cl- yet dominant in the 
coordination sphere) and turns greenish within hours (sizeable 
aquation), then black at longer time because of the Ru(IV) 
polyoxoruthenate species formation, characterised by 
Ru(IV)-On-Ru(IV) bridges. The time scale of this sequence of 
events has been demonstrated to depend on several factors, 
including pH and Cl- concentration. The ligand exchange process 
quickly begins with the release of the DMSO group, which can be 
observed exclusively in the solid state indeed. Afterwards, at least 
Figure 41 – Chemical structures of the most representative Ru-based compounds NAMI-A and 
KP1019 as compared to the novel pyridine-substituted AziRu complex (refer to body text and 
section 1.5. 
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three out of the four Cl- anions are replaced by H2O/OH-, 
depending on the pH: the higher the pH296 and the lower the Cl-,18,297 
the faster the process. The course of events goes on until the Ru(IV) 
polyoxoruthenate species responsible for the black colour appear. 
This stage goes as faster as higher the Cl- concentration possibly 
suggesting the involvement of a leaving chlorine group. 
Herein, a combined crystallographic-Raman structural study of 
AziRu with a model protein (lysozyme), focusing on the 
chemical-mediated Ru reduction and its release from the protein. 
Three reducing agents have been used in a twofold strategy: 1) 
crystallography has been used to identify the structural changes and 
release occurring upon Ru(III) reduction to Ru(II) by alternative 
exposure to hydrazine, ascorbate or sodium borohydride and 2) 
Raman microscopy on protein single crystals has been performed 
to identify the spectral changes due to the reduction of Ru(III) 
bound to the protein. Here-hence this study is meant to clarify 
whether a) ruthenium ion gets actually released from lysozyme 
upon chemical reduction and b) Raman can distinguish Ru 
coordination/oxidation state and detect Ru(II) release. 
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 Experimental 
HEWL crystals have been grown by hanging-drop vapour diffusion 
mixing 1 μL of 15 mg/mL protein in sodium acetate at pH 4.5 to 
1 μL of sodium chloride 1.1 M, sodium acetate 50 mM at pH 4.5. 
Very well-shaped crystals had rapidly grown within 48 h and have 
been soaked by merging a 2 μL drop of a 15 mM AziRu aqueous 
solution to the 2 μL crystal drop. The solution had suddenly turned 
yellowish and so have had the crystals upon AziRu exposure, thus 
turning to a greenish colouration in a timescale of hours and 
eventually had become dark brown/black in 1 week. Crystals had 
been kept at 20 °C throughout the whole crystallization, soaking 
and colour shift process. Raman data have been collected at 
increasing time from soaking until the formation of black crystals 
by using a commercial Jasco NSR-3100, a 514 nm excitation laser 
line (3 mW at sample power, 20x lens) directly in the crystallization 
well. 
Black crystals have been exposed to the alternative reduction with 
sodium borohydride, hydrazine, and ascorbate. Different reducing 
agent concentrations have been tested (10-100 mM) but no 
significant differences have to be reported. The best looking black 
crystals have been chosen for the X-ray data collection, which had 
been performed using a Saturn944 CCD detector along with CuKα 
X-ray radiation from a Rigaku Micromax 007 HF generator, and 
processed using HKL2000.299 The very same black crystal used for 
the reference dataset collection has undergone to reduction and 
hence re-used for X-ray data collection. The phasing has been 
carried out by molecular replacement using PhaserMR300 and the 
4J1B model from the PDB as template. Crystallographic 
refinements have been performed using Coot 0.8.6,280 and 
REFMAC5 from the CCP4 software suite.279 
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 Results 
Upon exposure to the AziRu solution, the lysozyme native crystals 
have swiftly turned yellowish (minutes), then greenish (hours) and 
lately black (≥1 week), consistently with previous records.18,297 As far 
as this text is drafted, black crystals have been stable for 1 year. 
The Raman spectra from the native ad black crystals have been 
collected as starting references for the reduction/release process 
(Figure 42). The black crystal trace shows very strong Raman bands 
in the low frequency region arising from the Ru(III)-OH2/OH- 
(400-500 cm-1) and Ru(IV)-O-Ru(IV) (500-700 cm-1) accordingly 
to previous assignment.18,297 The crystallographic structure of the 
black crystal has been solved (Table 6, Figure 43A) and, as expected, 
the model closely resembles the previously solved structure (PDB 
accession 4J1B).297 The Ru binding site is appreciable nearby the 
His15 side chain (Ru-NE2 at 2.4 Å) and its occupancy has been 
evaluated as 0.5. The ruthenium bound to the His15 exhibits 
octahedral geometry tough the sixth ligand (wat in Figure 43A and 
C) could not be interpreted as part of the Ru coordination sphere 
because of the significant geometrical distortion. This can be 
possibly made plain with the steric hindrance from the very close 
Asp87 side chain. 
Chemical reduction has been performed on black crystals using 
three different reducing agents. The exposure to borohydride has 
rapidly wreaked the crystal, like enough because of the might 
hydrogen sparkling and neither Raman nor crystallographic 
investigations have been possible. By contrast, hydrazine has driven 
to a colourless, native-like crystal whose Raman spectrum and 
crystallographic structure (Figure 43B) are utterly 
undistinguishable from native lysozyme crystals grown in the same 
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conditions, clearly indicatory of a complete release of Ru from the 
protein upon reduction, like enough through: (1(222)(3453678)-:;)< → (1(22)(3453678)-:;)< → (1(22)(3453678) 
In fact, upon hydrazine addition the X-ray structure, solved at 
2.55 Å and refined up to R and Rfree of 0.193 and 0.293 respectively, 
does not show any residual Ru density (Figure 43B) and resembles 
the structure of wild-type lysozyme crystals grown in the same 
conditions (Figure 43D, PDB 5L9J) as also confirmed by the low 
0.279 Å RMSD calculated by superposing the hydrazine-reduced 
model to the PDB 5L9J.301 
By contrast, upon reduction with ascorbate the black crystal has 
turned back to green and stably remained so, long enough to allow 
for Raman and X-ray diffraction data collections.  
The Raman spectrum distinctly changes losing completely the very 
strong Ru(III)-H2O/OH- signals in the low frequency region (Green 
Figure 42 – Non-resonant Raman for the reduction of lysozyme-AziRu(III) (black crystal) the 
lysozyme-AziRu(II) (green crystals) upon ascorbate exposure. Wild-type lysozyme crystal 
spectrum is also reported as a reference, as well as mother liquor from green and black crystal 
either. Spectral features marked as (*) refer to signals from the mother liquor, whereas those 
labelled with (#) refer to signals arising from ascorbate.  
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crystal trace in Figure 42), whilst a new spectral feature arises at 
around 606 cm-1. Literature does not support for any Ru(II)-protein 
species assignment. Gas-phase DFT calculations are being 
performed to explore possible Ru(II)-related modes.  
The crystallographic structure for the ascorbate-reduced crystal 
(Green crystal) has been solved at 1.86 Å and refined up to R and 
Rfree of 0.178 and 0.255 respectively (Table 6). Differently from the 
crystal reduced with hydrazine, it has revealed the persistence of the 
Ru atom bound to the His15 with almost no differences as 
compared to the black crystal structure (Figure 43C). 
Figure 43 – Crystallographic close up for the His15 Ru binding site. All models are countered with 
2Fo-Fc at 1σ (grey mesh) and 3σ (purple mesh). For sake of clarity, non-interacting water have 
been hidden. A) Detail for the Black crystal before the chemical reduction. B) Upon reduction 
with hydrazine no Ru density is detectable. C) Upon reduction with ascorbate no significant 
structural modifications are appreciable and Ru density is almost unperturbed. D) The native 
lysozyme structure from crystals grown in the same condition is reported as reference (PDB 5L9J). 
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Electron-density maps indicate that no disulphide reduction occurs 
and the Ru site keeps its occupancy and coordination geometry. 
The RMSD value obtained by superposing the Green over the Black 
crystal is as low as 0.125 Å, denoting the models to be almost 
identical. 
The aggregate of the disappearing Ru(III)-H2O/OH- Raman 
features, persisting Ru-density and geometry in the reduced crystal 
structure, indicates that upon ascorbate addition a Ru(II) specie 
bound to the protein could have been trapped, schematically as: (1 222 3453678-:;)< → (1(22)3453678-:;)< 
In this case, no Ru(II) release is observed, thus ascorbate is able to 
reduce Ru(III) to Ru(II) yet bound to protein without triggering the 
Ru release as seen with hydrazine, at least in our experimental 
condition. 
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Table 6 – Refinement statistics for the AziRu soaked crystal (Black), the ascorbate reduced (Green) 
and the hydrazine reduced (Colourless) crystals. 
 
Black	crystal	(AziRu	soaked)	 Green	crystal	(ascorbate)	 Colourless	crystal	(hydrazine)	Resolution	(Å) 2.31	[2.25]	 1.91	[1.86]	 2.62	[2.55]		Working	set	(n.) 5073	 9339	 3783	Test	set	(n.) 251	 467	 179	Rfactor	(%)	 18.7	 17.8	 19.3	Rfree	(%)	 28.1	 25.5	 29.3	Rall	(%)	 19.16	 18.31	 20.1	Non-hydrogen	atoms	(N.)	 1164	 1177	 1103	Mean	B-value	(Å2)	 42.88	 35.33	 45.11	Favoured	(%)	 98.4	 98.4	 92.1	Allowed	(%)	 1.6	 1.6	 7.9	Outliners	(%)	 0	 0	 0	
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 Conclusions 
Raman-assisted crystallography has been applied to the structural 
characterisation of the chemically induced reduction of the 
ruthenium prodrug AziRu bound to protein crystals. The outcome 
evidently hangs on the reducing agent. Hydrazine has brought to 
native-like lysozyme crystal since no trace of residual ruthenium 
electron-density has been found and the Raman spectrum is utterly 
identical to the native one, convincingly supportive for the Ru 
release from the protein. By contrast, ascorbate has yielded the 
AziRu-soaked black crystal (Ru(II)/Ru(III)) firmly back to green 
(Ru(II)). This has come besides thorough modifications of the 
Ru-related Raman features, albeit no perturbation in the 
crystallographic structure has been appreciable. 
These findings open new structural and spectroscopic insights on 
the reduction-dependent ruthenium prodrug activation and release 
from proteins, a key point in the bigger selective drugging picture. 
Additional corroborations are reported in the chapter to come but 
blind spots remain regardless. To this end, gas-phase DFT 
calculations are being performed by prof. Hildebrandt’s team at the 
Technische Universität of Berlin. Next chapter addresses for the 
investigation of key physical-chemical forces driving the ruthenium 
prodrug activation by means of SERS electro-spectroscopy and 
voltammetry.   
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8 
On-electrode 
Ruthenium prodrug 
SERS 
 
his section accounts for the investigation of some key 
physical-chemical properties of the Ru-based prodrug AziRu, 
relevant in terms of pharmacokinetics and dynamics, deepening the 
structural considerations on Ru release process reported in Chapter 7. 
The potential- and pH-dependent behaviours of AziRu have been 
studied through a SERS-based approach giving interesting clues on 
the possible selective drug release and activation within cancer 
environment. The investigation has been conducted in the 
laboratories of professor Peter Hildebrandt at the Institut für 
Chemie, Technischen Universität – Berlin.  
T 
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 Introduction 
The drug effectiveness goes far beyond its mere cytotoxic or 
anti-proliferative activities as it does not matter how powerful the 
drug if the fix gets worse than the illness itself. The utmost pressing 
and trending topic in current drug design course is selectivity, 
meant as a whole of pharmacological facets making a drug able to 
pick out malignant targets avoiding regrettable impacts on healthy 
cells, tissue, physiological pathways etc. Selectivity is attained 
mostly by means of two routes: a) selective drug delivery and b) 
selective drug activation. The former includes deploying 
nanocarriers, nanoparticles, molecular decoration etc., whereas the 
latter can be achieved through diverse approaches e.g. 
photo-mediated, pH or redox dependent activation.4 
Cancer cells and tissues indeed exhibit a bunch of sizeably different 
chemical features as compared to healthy ones, which can be 
exploited as target labelling features. The high proliferation rate of 
transformed cells prompts severe increase of hypoxia metabolism 
and therefore an extracellular lumen pH acidification as low as 6, as 
compared to the physiological 7.4.4 In addition, tumour 
progression invariably goes through hindering the ROS processing 
ability giving rise to more radical-rich reducing environment.302 
The “activation by reduction” hypothesis,64,82,87 first advanced for 
platinum prodrugs, applies to every system able to access its active 
drug form upon reduction, or oxidation by extent, within 
malignant conditions. Ruthenium complexes are fully compliant to 
this definition as the Ru(II) is anticancer active,61,82,83 whereas its 
oxidised counterpart Ru(III) is not, yet much more stable under 
physiological conditions in return.4,16,58,64,81 
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The novel Ru(III) prodrug AziRu (Figure 41), derived from 
NAMI-A, whose chemical-prompted reduction from a structural 
point of view is dealt in Chapter 7, does not make exception. 
This section goes into investigating the AziRu pH- and reduction 
potential-related behaviours by means of Surface Enhanced Raman 
Spectroscopy (SERS) performed on electrodes at controlled applied 
potential, to grasp whether AziRu is compatible with a selective pH- 
and/or reduction potential-related activation within cancerous 
surroundings. Indeed, earlier studies on its parent compound 
(NAMI-A) have demonstrated the pH to sensibly affect the ligands 
exchange kinetics and the Ru(III)/Ru(II) redox potential by way of 
H2O/OH- shift.303 
For the sake of the electrodes functionalisation this study has been 
carried on by using the AziRu derivative compound as reported 
below (Figure 44): 
 
  
Figure 44 – AziRu derivate compound used for on-electrode SERS 
experiments. The disulphide grants high reactivity towards the Au 
surface.  
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 Experimental 
The disulphide derivate of AziRu has been synthesised by prof. 
Montesarchio and co-workers whereas all of the experimental 
activities to follow have been carried out within the laboratories of 
prof. Peter Hildebrandt and the precious support of dr. Jacek 
Kozuch, during my stay in Berlin. 
8.2.1 Electrodes preparation 
Silver and gold ring electrodes either have been tested in 
combination with different laser lines (413, 514 and 647 nm) for the 
purpose of SERS collections. Satisfactory results have been achieved 
with gold electrodes combined with the 647 nm line, and the 
information to follow are to be meant as solely referred to Au 
electrodes from now on. 
The success of the electrode functionalisation process strictly 
depends on a proper and deep cleaning of its surface, made 
throughout a mechanical, chemical and electro-chemical 
procedure. 
A first rough mechanical cleaning step relies on using abrasive fine 
dust and sandpaper with progressively narrowing texture, hence 
washes with distilled water. The electrode is afterwards immerged 
into a 1:1 (v/v) hydrogen peroxide/sulphuric acid solution till the 
complete reaction exhaustion for the harsher chemical treatment, 
washed again with water and finally dipped into an ultrasonic bath 
for at least 15 minutes and rinsed with water again.  
A last, the gold surface roughening goes through an electrochemical 
process by using potassium chloride 0.1 M as electrolyte solution 
and hundreds of redox cycles under protective argon atmosphere. 
A very similar process has been adopted to prepare pin gold 
electrodes deployed for cyclic voltammetry measures. 
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8.2.2 Laying down AziRu monolayer 
Gold ring electrodes are now ready for a final thorough wash with 
distilled water/ethanol, hence carefully dried under nitrogen flux. 
AziRu self-assembled monolayer (AziRU-SAM) is obtained by 
dipping the so prepared electrode into a 1:1 water/ethanol 15 mM 
AziRu derivate solution, the bowl cautiously sealed with Parafilm® 
and kept in the dark for 1 day. The same procedure has been 
wielded for pyridine self-assembled monolayers. 
8.2.3 SERS setup 
The functionalised gold ring electrodes have been mounted on a 
spinning axis within a 10 mL electrochemical windowed cell. 
During the measurements, the axis has been kept spinning at 
200 Hz to reduce laser-induced photochemical reaction of the 
AziRu SAM. The gold ring itself serves as working electrode, 
coupled with an Ag/AgCl and a platinum electrode as reference and 
counter respectively. The gold mounting axis is connected to a 
speed-controlled motor and to the potentiostat. 
Raman spectra have been collected by using a LabRAM HR800 
system equipped with an Olympus BX41 microscope, a 20x wide 
aperture and long focus distance lens from Nikon, and a 647 nm 
Coherent Innova Kr+ laser line as source. A Peltier-cooled Andor 
CCD as detector operating at -70 °C and a 180° oriented notch filter 
complete the setup. All reported spectra have been recorded at 
room temperature, 1 mW on sample power and spectral resolution 
of 1 cm-1. A schematic representation of the experimental setup is 
reported in Figure 45. 
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For sake of conciseness, all of the buffers used in this work are, if 
not differently explicated, as follow:  
• 10 mM Na2B4O7/NaOH 100 mM KCl – pH 10 
• 10 mM Na2HPO4/NaH2PO4,100 mM KCl – pH 7 
• 10 mM Na/Acetate, 100 mM KCl –  pH 4 
and pH accordingly adjusted for intermediate values. 
 
Figure 45 – On-electrode experimental setup scheme. A Teflon windowed chamber contains an 
AziRu-SAM functionalised gold working electrode in fixed to a spinning motor to avoid laser-
induced effects. It is also connected to a potentiostat system for fine-tuning the applied potential. 
Ag and Pt electrodes are used as reference and counter respectively. The Teflon chamber is filled 
with buffer solution. The setup requires a 20x long working distance, wide-aperture lens and laser 
focus is adjusted manually by moving the entire Teflon chamber. Finer adjustments are performed 
using fine-tuning screws on the chamber mounting frame (not drawn).  
8.2.4 Cyclic voltammetry setup 
Gold pin working electrodes have been inserted into a glass 
measuring cell. Again, Ag/AgCl as reference and platinum as 
counter electrodes. Measured potential have ranged 
between -0.55 V and +0.60 V with a scanning speed of 50 mV·s-1, 
invariably under protective argon atmosphere. 
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 Results 
Raman references for the vibrations of the Ru complex have been 
obtained from the comparison between the SERS spectra from the 
AziRu and pyridine self-assembled monolayers (Figure 46A). The 
1000-1700 cm-1 region of the AziRu spectrum is entirely due to 
pyridine (Py from now on) ring modes. 
Significant signals from the ruthenium-ligand vibrations are 
appreciable in the 200-1000 cm-1 region, though some Py features 
superpose. 
The identification of Raman markers for the ligand exchange upon 
water exposure has been achieved by comparing the low frequency 
regions from the dry AziRu spectrum to the AziRu spectrum 
collected in the presence of the buffer, a 10 mM sodium phosphate, 
100 mM potassium chloride solution at pH 7 (Figure 46B). The 
comparison marks clear changes in the relative intensity of lower 
frequency features upon dry to “wet” AziRu transition. The bands 
from Ru-Cl modes decrease due to the very fast Cl → H2O/OH- 
exchange, according to previous findings18,297 and consistently with 
two arising features related to Ru-H2O/OH in the range 
300-500 cm-1 and at around 750 cm-1 (Figure 46B). Noteworthy that 
ruthenium-oxygen vibrations are present in the dry spectrum 
conceivably indicating the ligand exchange to already take place in 
the 50% v/v ethanol solution used for functionalising the ring 
electrode. Casting out nines to pinpointedly assign these spectral 
modifications to Ru-ligands exchange, the dry Py and wet Py 
spectra have been collected (Figure 47) and the comparison does 
not show any appreciable difference, thus confirming the exclusive 
Ru coordination sphere involvement. 
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These evidences are useful to assume a low content of Ru-Cl in the 
wet condition (probably only one Cl- remains coordinated in the 
time scale of SERS measurements), and consistent with previous 
observations.18 
The strong SERS differences between Aziru-SAM and Py-SAM 
translate into valuable SERS markers for the Ru-release. Particularly:  
a) the regions at 300-500 and at around 750 cm-1 are very 
different prior and after Ru-release. 
b) the relative intensities of the two bands around 1600 and 
1200 cm-1 are sensitive to the ruthenium release as well. 
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Figure 46 – SERS spectra collected on ring gold electrodes using a 687 cm-1 excitation line. A) 
Comparison between dry pyridine and dry AziRu self-assembled monolayers. Spectral differences 
allow to assign Ru-related vibrational modes as highlighted in red boxes. B) Low frequency detail 
for the comparison between dry AziRu SAM and its “wet” counterpart in a 10 mM Na2HPO4, 10 
mM NaH2PO4, 100 mM KCl solution at pH 7. Relative intensity variations are appreciable, that 
is, Ru-Cl features fade out and Ru-H2O/OH- bands arise, coherently with a swift ligand exchange. 
A 
B 
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8.3.1 investigating SERS of AziRu vs pH 
Upon aquation, the pH has a pivotal role in defining the 
electrochemical properties and behaviour of the complex by means 
of the H2O/OH- ligands ratio hence Ru(III)/Ru(II) redox potential 
and ultimately affecting the promising AziRu selective activation. 
A first concern is about whether protonation/deprotonation 
actually occur and this SERS experimental setup is able to detect 
them. Thereafter, attempt to determine the pKA value accordingly. 
Given the previously obtained Raman references for the aquation 
process, SERS spectra of the wet AziRu SAM as a function of pH 
have been collected at 7 pH values, between 4 and 10 (Figure 48). 
The ≥1000 cm-1 region (Figure 48A) is utterly unperturbed by pH, 
whereas the low frequency features significantly vary as pH changes 
(Figure 48B). Particularly, the relative intensities of the bands in the 
400-500 cm-1 range, diagnostic for the H2O/OH- vibrations, revert 
as pH arises. The 420 cm-1 band prevailing at pH 10, can be assumed 
Figure 47 – SERS spectra comparison between dry pyridine SAM and the wet pyridine SAM 
dipped in a 10 mM Na2HPO4, 10 mM NaH2PO4, 100 mM KCl solution at pH 7. Spectra collected 
using a ring gold electrode and 687 nm laser line. Spectral resolution is 1 cm-1. 
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as representative for Ru-OH- and, accordingly, the 480 cm-1 as 
diagnostic of the Ru-H2O modes. A minor shift of the band at 
around 720-740 cm-1 is also appreciable. 
Figure 48 – SERS spectra at different pH for the AziRu SAM. A) The full range spectra point out 
that no significant modification occurs beyond 1000 cm-1. B) Detail for the low frequency region 
show a clear inversion in the relative intensities of the 420 and 480 cm-1 bands, assumed as 
representative for Ru-hydroxide and Ru-water respectively.  
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The SERS spectra have been collected also from the Py SAM at the 
same pH values as before (Figure 49). The Py SAM spectrum at 
pH 4 shows a 1640 cm-1 shoulder due to the pyridine protonation 
(ν N-H), absent at pH 7 and 10 either. No additional changes in the 
low frequency region are detectable thus excluding Py-related 
effects on the spectral changes seen from the pH-dependent AziRu 
spectra. 
8.3.2 Determining the pKa 
The pH-sensitive SERS features above described are the ground for 
a tentative extrapolation of the pKa value for the H2O/OH- 
deprotonation in the Ru-coordination sphere. Indeed, a first 
evaluation of the pKa value can be useful to understand whether it 
falls within a suitable range for the selective prodrug activation, 
bearing in mind the substantial difference in pH between healthy 
and cancerous environments (7.4 down to 6 respectively).4 This pKa 
determination has been performed by means of SERS spectra from 
Figure 49 – SERS spectra from the pyridine SAM at pH 4, 7, and 10. A shoulder at 1640 cm-1 is 
appreciable in the pH 4 trace exclusively and it is diagnostic for the Py protonation. 
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the AziRu self-assembled monolayer undergoing to a pH tritation 
spanning in the pH range 4-10, with 1 pH steps between successive 
records (Figure 50).  
The pKa evaluation herein proposed relies on the assumption that 
at pH 10 uniquely the protonated form exists since there is almost 
no difference between spectra collected at pH 9 and 10. Therefore, 
the pH 10 spectrum has been regarded to be representative for a 
single Ru-OH- specie with a molar fraction of 1. 
By contrast, the pH 4 spectrum cannot be regarded as 
representative of a single Ru-H2O specie since clear differences still 
occur between pH 4 and 5. A clear plateau is not appreciable, 
hinting the transition is far from complete and the Ru-H2O fraction 
is lower than 1 at pH 4.  
A putative pure Ru-H2O spectrum has been achieved by subtracting 
the spectrum at pH 10 from the one at pH 4. 
Figure 50 – SERS spectra collected at different pH values in the 4-10 range. All of the spectra 
have been collected from the same functionalised gold electrode by substituting the buffer 
solution and waiting 10 minutes for equilibration. Significant spectral changes are appreciable 
in the low frequency, particularly in the 300-500 cm-1 range. By assuming a single 
deprotonated specie at pH 10, the pKa has been determined (see body text). 
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Making it simpler, the pH 4 spectrum is representative for a 
residual deprotonated fraction of 0.16, hence of a 0.84 fraction of 
Ru-H2O. The relative molar fractions for each collected spectrum 
(from pH 4 to 10) have been extrapolated, plotted (Figure 51) as a 
function of pH and fitted using the Boltzmann equation.  
The pKa value could therefore be evaluated to be 6.4±0.1, a most 
interesting inference because compatible with the hypothesis that 
lower pH found in cancerous tissues and cells may crucially 
contribute to selectively prompt the prodrug activation by 
favouring the transition to the Ru(II) active specie.4 
These findings remarks the chance to effectively use AriRu SAM as 
a SERS pH sensing system, at least in the 5.4-7.4 pH range by using 
the useful ration between the bands at 420 and around 480 cm-1. 
Moreover, the SERS could make this possible in-cell as well. 
8.3.3 Electro-SERS 
Potential-dependent SERS has been used to determine the 
behaviour of the AziRu at different applied potentials at different 
Figure 51 – Molar fraction as a function of pH for the Ru-OH (RuOH) and the Ru-H2O species. 
A sigmoidal trend is appreciable and a Boltzmann fitting performed (fitting table). The pKa value 
as been determined to be 6.4.  
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pH conditions. AziRu SAM on a ring gold electrode have been 
exposed to pH 4, 7 (Figure 52A and B) and 10 (Figure 53) and 
spectra recorded as a function of controlled applied potential 
spanning in the -300 mV +500 mV range, by using a potentiostat 
directly linked to the gold ring, which serves as working electrode. 
Major changes occur upon applied potential and pH variation 
either. Significant changes are apparent mostly in the lower 
frequency region representative for the Ru-ligands modes. The 
band at around 1620 cm-1, arising from the Py-ring stretching 
normal modes (C=C)304,305 is expected to be sensitive towards the Au 
surface and the ruthenium electron density either and has been first 
evaluated as diagnostic of the redox process and used for a tentative 
E0 evaluation.305,306 
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8.3.3.1 pH 4 
The SERS spectra at pH 4 remark noticeably modifications, 
particularly in the lower frequency region, representative for the 
Ru-ligands modes. These features decrease in intensity till nearly 
completely disappearing at approximately -100 mV, whereas the 
Figure 52 – SERS spectra for the AziRu SAM at A) pH 4 and B) pH 7 at different applied potentials 
in the -300 mV to +500 mV. A clear trend is apparent at pH 4 for the low frequency region signals 
arising from the Ru-ligand modes, indicatory for the ruthenium release. Besides, the relative 
intensity of the Py-related bands at 1060 and 1620 cm-1 changes accordingly. At pH 7 there is not 
a clear trend remarking the pH dependency. 
A 
B 
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Py-related bands stand (Figure 52), indicating Ru release. The Py 
ring breathing band at around 1020 cm-1 stays completely 
unperturbed but the Py-ring trigonal breathing,304,305 around 1060 
cm-1 decreases. The Py-ring C=C stretching band at around 1620 
cm-1 shifts as the potential becomes more negative (Figure 52) and 
has been used to evaluate putative E0 by assuming the system to be 
completely oxidised at +500 mV and completely reduced 
at -300 mV, using the same approach as seen for the pKa. At pH 4 
the E0 extrapolated from SERS spectra is +28±7 mV. 
Worth to say, this SERS-based redox titration is definitively less 
accurate than the previously reported SERS-based pH-titration, 
and alternative route for evaluating the E0 evaluation has been 
adopted (see below). It has therefore not to be considered as a 
reliable SERS-based redox sensing system. 
The very sharp trend observed for the lower frequency region 
features from the Ru-ligands can possibly relate to the release of the 
ruthenium from the pyridine upon reduction. The behaviour in this 
region is completely different both at pH 7 and pH 10, potentially 
supporting the opening hypothesis, though further proofs are 
needed. 
8.3.3.2 pH 7 and pH 10 
Looking at the SERS spectra sequence a pH 7 the AziRu behaviour 
is sensibly different. The mighty drops in intensity in the low 
frequency region are not appreciable but for a slight reduction of 
the feature at around 750 cm-1. As well, the relative intensities of the 
Py-ring breathing modes do not appear perturbed by the applied 
potential all over its full extent. The C=C Py-ring band at around 
1620 cm-1 shifts less pronouncedly than seen at pH 4 and the 
resulting fitting model is affected by a larger bias, giving an E0 value 
of 208±20 mV. 
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Similarly, at pH 10 the bands in the lower frequency have a similar 
behaviour as at pH 7 though, even though some new species 
conceivably appear. In this case, the estimated E0 value is 
103±5 mV. 
Though clear pH- and potential-dependent SERS spectral features 
have been identified, the found E0 values yet glares curbs and a 
deeper investigation has been performed by means of cyclic 
voltammetry. 
8.3.4 Cyclic voltammetry 
Cyclic voltammetry has been performed on the same system 
adopted in the Raman-based evaluation of standard reduction 
potentials, but for the usage of pin gold electrode in place of ring 
ones. Resulting voltammograms are reported in (Figure 54), and a 
clear dependence towards pH is apparent. 
The pH 10 voltammogram shows a different course over the 
number of cycles as compared to pH 7 and 4 (Figure 54). Some 
features clearly visible in early runs fade out and new signals arise.  
Figure 53 – SERS spectra for the AziRu SAM at pH 10. The lower frequency bands exhibit a similar 
behaviour as compared to pH though new, yet unidentified species, appear. 
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This can possibly be explained by the electrically-driven formation 
of unstable species rapidly changing in new, stable species, also 
pH 10 
pH 7 
pH 4 
Figure 54 – Cyclic voltammograms at the three different pH values of the 
AziRu SAM vs Ag/AgCl on a pin gold electrode. At pH 10 the system is 
probably far from an equilibrium condition.  
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making plain the stabilisation as the number of cycles goes. 
Alternatively, the system may be far from the equilibrium during 
early stages though the previous SERS findings hardly fit. 
Moreover, even much longer equilibration times prior the 
cyclo-voltammetric measures have given almost identical results.  
The voltammograms have a very broad appearance which may be 
clarified as the addition of multiple different species possibly 
possessing very close E0 values, but further investigations are 
required. 
The voltammetric evaluation of the E0 for each pH has been hence 
brought off according to: ;m = ;#n + ;p782  
where Eox and Ered are the standard oxidation and reduction 
potentials respectively. As compared to those obtained from SERS, 
the cyclic voltammetry gave a much clearer trend. As the pH moves 
down, the corresponding standard E0 values moves from -200 mV 
at pH 10, to -50 mV at pH 7 and -34 mV at pH 4 finally. 
The aggregate of the pKa (6.4±0.1) and the E0 findings, gives an 
encouraging frame for the easier reduction, thus activation of the 
AziRu prodrug within cancer entities, bearing in mind the 
comparatively lower pH and higher reducing environment of 
tumours as compared to healthy tissues. 
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 Conclusions 
AziRu is among the most promising prodrug from the ruthenium 
family because of its stunning anti-proliferative, anti-metastatic, 
and likely selectivity properties. The keystone hypothesis 
underlying the selective activation of the prodrug harks back to 
whether the reduction of the ruthenium within cancerous lesions 
could occur easier than in physiological counterparts, because of 
lower pH and sensibly higher reducing potential of cancerous 
conditions. This section addresses this question by giving insights 
on the influence pH exerts on the standard reduction potential of 
the complex, through the interesting SERS on electrode approach. 
Further support to the previous Ru-ligands assignment is provided 
and an evaluation of the pKa is reported. 
Briefly, this chapter brought two significant inferences: 
I. Provides the pKa and E0 values as a function of pH for the 
AziRu SAM. 
II. Proves the sensitiveness of the SERS valuable for 
developing diagnostic systems for the pH and the 
ruthenium release either, possibly transposable to in-cell 
applications. Regrettably, the system cannot be assumed 
reliable for the Ru-detection as yet. 
The most interesting pKa value of 6.4±0.1 falls in a watershed range 
of pH values separating most cancer environments from their 
physiological counterparts. Standard reduction potentials have 
been thereafter evaluated as a function of pH by means of 
electro-SERS and cyclic voltammetry either. Though the outcomes 
from electro-SERS have not been as clear as cyclic voltammetry, E0 
values could be evaluated showing a meaningful trend with regard 
to the pH. The whole of these findings further proves the chance for 
a selectively easier, potential-driven and pH-dependent activation 
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of the ruthenium prodrug within cancer. Further theoretical DFT 
and Levers’ analyses307 are being brought off by dr. Kozuch and prof. 
Hildebrandt’s team, preliminarily supporting these findings. 
Looking forward, SERS analyses should be extended further acid 
since the pKa sigmoidal plateau is not entirely shaped at pH 4. By 
now, this has been denied by limitations in the electrochemical cell 
used. At last, UV/Vis electrospectroscopy could profitably integrate 
SERS findings.  
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9 
Bottom line 
This project dealt with the improvement of the relatively young yet 
powerful Raman-assisted crystallography (RAC) approach, a most 
convenient combination of mutual complementary techniques for 
looking deep into the bountifully informative macromolecular 
crystalline systems. RAC was applied to explore a number of most 
diverse systems exploiting metal-protein interaction as a common 
thread subject. 
Each foregoing section extensively accounts for system-specific 
inferences whereas a comprehensive discussion over the general 
forewords of this thesis follows. 
Raman assistance turns useful as a supportive tool for a bounty of 
goals and was effectively exploited as a supportive analytical tool for 
assessing primary structure (ligands insertion in Chapter 2, 
photodamage events in Chapter 3) and secondary structure 
(q → r transition in Chapter 2) chemical modifications occurring 
within protein crystals. 
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Beyond the purely compositional information and in a stricter 
sense of the words, RAC was fruitfully adopted to overcome 
crystallographic curbs in terms of supportive or complementary 
data for the electron-density disambiguation (Chapters 5-7), to 
proper clarify ligand binding-mode (Chapter 5), metal 
coordination sphere (Chapters 6 and 7) and redox behaviour 
(Chapter 7). In addition, in-cristallo Surface-Enhanced Raman 
Spectroscopy (SERS) provided inspiring information for a proper 
crystallographic structural evaluation of a protein-nanoparticle 
hybrid system (Chapter 3), while off-crystal, on-electrode SERS 
emerged into a fine setup for the investigation of key 
physico-chemical properties of a novel ruthenium prodrug 
(Chapter 8). 
Altogether, this thesis proved the RAC effectiveness and reliability 
in a swollen range of diverse protein-metal systems and hints to 
overturn the RAC perspective as crystallography provided valuable 
support for Raman assignments, in a Crystallography-assisted 
Raman spectroscopy (CAR) outlook, as led out in Chapter 3 where 
ultrahigh resolution X-ray data was the spearhead for satisfactory 
Raman markers identification, and in Chapter 5 where Raman and 
crystallography came to mutual assistance iteratively. 
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